{"gene":"LPL","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1987,"finding":"Human lipoprotein lipase (LPL) cDNA was cloned and sequenced, revealing a mature protein of 448 amino acids and identifying LPL as a member of a gene family that includes hepatic lipase and pancreatic lipase. Two distinct LPL mRNA species arising from alternative 3'-polyadenylation sites were detected in multiple tissues.","method":"cDNA cloning and sequencing","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — foundational molecular characterization, primary sequence determination","pmids":["3823907"],"is_preprint":false},{"year":1985,"finding":"ApoC-III directly inhibits LPL activity in a non-competitive manner, as demonstrated by kinetic analyses of LPL-mediated hydrolysis of VLDL in the presence of purified ApoC-III-2, suggesting ApoC-III directly interacts with LPL.","method":"In vitro LPL activity assay with purified apolipoprotein, kinetic analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with kinetic analysis, replicated in subsequent work","pmids":["3973011"],"is_preprint":false},{"year":2002,"finding":"LPL catalyzes hydrolysis of the triacylglycerol component of chylomicrons and VLDL, providing non-esterified fatty acids and 2-monoacylglycerol to tissues, and also possesses non-catalytic functions including bridging lipoproteins to cell-surface receptors and proteoglycans. Domain-function relationships established multiple LPL functional regions.","method":"Review synthesizing biochemical, mutagenesis, and transgenic animal studies","journal":"Journal of molecular medicine","confidence":"High","confidence_rationale":"Tier 1–2 — synthesis of extensive experimental literature with domain-function mapping","pmids":["12483461"],"is_preprint":false},{"year":2001,"finding":"Catalytically inactive LPL alone (in the absence of active LPL) is sufficient to mediate selective cholesterol ester uptake from triglyceride-rich lipoproteins, but triglyceride hydrolysis and whole-particle lipoprotein uptake require active LPL. This demonstrates distinct catalytic and non-catalytic receptor-bridging functions of LPL.","method":"Transgenic mouse models breeding catalytically inactive LPL transgene onto LPL-deficient backgrounds; radiolabeled lipoprotein uptake assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple transgenic mouse models with orthogonal readouts distinguishing catalytic from bridging functions","pmids":["11751882"],"is_preprint":false},{"year":2014,"finding":"GPIHBP1-bound LPL (not free LPL nor HSPG-bound LPL) is the principal determinant of triglyceride-rich lipoprotein (TRL) margination in heart capillaries. Fluorescence microscopy, infrared-dye-labeled lipoprotein assays, and EM tomography showed TRLs fail to marginate in Gpihbp1-/- mice even when LPL is expressed by endothelial cells and available on HSPGs.","method":"Fluorescence microscopy, quantitative lipoprotein margination assays, EM tomography in wild-type and Gpihbp1-/- mice","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal imaging and quantitative methods in genetic mouse model","pmids":["24726386"],"is_preprint":false},{"year":2014,"finding":"Sel1L, an ER-associated degradation adaptor protein, physically interacts with and stabilizes the LPL maturation complex comprising LPL and LMF1. In the absence of Sel1L, LPL is retained in the ER, forms protein aggregates, and is degraded primarily by autophagy rather than being secreted.","method":"Adipocyte-specific Sel1L knockout mice; co-immunoprecipitation; ER fractionation; autophagy inhibition experiments","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO with multiple orthogonal methods (co-IP, fractionation, rescue), replicated across cell types","pmids":["25066055"],"is_preprint":false},{"year":1999,"finding":"LPL is expressed in pancreatic islets and directly regulates insulin secretion: islet LPL suppresses insulin release. INS-1 cells with increased LPL activity secreted less insulin, and cells with antisense LPL knockdown secreted more insulin, establishing LPL as a novel regulator of insulin secretion.","method":"LPL-deficient mouse islet isolation; in vitro insulin secretion assays; AAV-mediated LPL overexpression and antisense LPL knockdown in INS-1 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function with defined secretory phenotype readout, islets and cell line","pmids":["10488074"],"is_preprint":false},{"year":2016,"finding":"HSPG-bound LPL in interstitial spaces is mobile and can detach from HSPGs to migrate to GPIHBP1 on capillary endothelial cells. This migration requires the Ly6 domain of GPIHBP1 (W109S mutation abolishes transfer) but not GPIHBP1's acidic domain. In vivo, GPIHBP1-coated agarose beads injected into GPIHBP1-deficient adipose tissue recruited LPL from adjacent adipocyte HSPGs.","method":"Cell culture mobility assays; GPIHBP1-coated agarose bead injection into adipose tissue of GPIHBP1-deficient mice; mutagenesis of GPIHBP1 domains","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro and in vivo experiments with defined GPIHBP1 domain mutants","pmids":["27811232"],"is_preprint":false},{"year":2017,"finding":"ApoC-III potently inhibits triglyceride hydrolysis by GPIHBP1-bound LPL to a greater extent than by free LPL. ApoC-III-enriched TRLs bound normally to GPIHBP1-bound LPL but were hydrolyzed more slowly. A natural ApoC-III variant (p.A23T) associated with low triglycerides showed reduced capacity to inhibit both free and GPIHBP1-bound LPL.","method":"Cell culture LPL-lipolysis assays with GPIHBP1-bound LPL on agarose beads; in vivo TRL binding assays in transgenic mouse hearts; recombinant apoC-III inhibition kinetics","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assays with GPIHBP1-bound LPL, supported by in vivo data and natural variant validation","pmids":["28694296"],"is_preprint":false},{"year":2018,"finding":"ANGPTL4 binds LPL near the active-site lid domain and an adjacent alpha-helix, as mapped by hydrogen-deuterium exchange mass spectrometry and validated by chimeric LPL variants and LPL peptide mimetics. Binding of ANGPTL4 to the lid domain likely prevents substrate catalysis at the active site.","method":"Hydrogen-deuterium exchange mass spectrometry; chimeric LPL variants; LPL peptide mimetics; in vitro LPL inhibition assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — HDX-MS structural mapping validated by mutagenesis and functional assays","pmids":["30591589"],"is_preprint":false},{"year":2021,"finding":"ApoA5 lowers triglycerides by suppressing ANGPTL3/8-mediated LPL inhibition rather than by directly activating LPL. ApoA5 associates with ANGPTL3/8 in human serum (demonstrated by immunoprecipitation-MS) and blocks ANGPTL3/8 from inhibiting LPL, but has no effect on ANGPTL3, ANGPTL4, or ANGPTL4/8-mediated LPL inhibition.","method":"Immunoprecipitation-mass spectrometry; biolayer interferometry; functional LPL enzymatic assays; kinetic analyses","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical methods including MS, biophysical binding, and functional enzyme assays","pmids":["33762177"],"is_preprint":false},{"year":2022,"finding":"LPL and ApoA5 bind the same leucine zipper-like epitope on the ANGPTL3/8 complex, consisting of N-terminal regions of ANGPTL3 and ANGPTL8 unmasked upon complex formation. An anti-ANGPTL3/8 antibody targeting this epitope potently blocked ANGPTL3/8-mediated LPL inhibition in vitro and dramatically lowered triglycerides in vivo.","method":"Hydrogen-deuterium exchange mass spectrometry; molecular modeling; biolayer interferometry; in vitro LPL inhibition assays; in vivo mouse TG measurements","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — structural mapping by HDX-MS with functional validation in vitro and in vivo","pmids":["35307397"],"is_preprint":false},{"year":2023,"finding":"The ANGPTL4/8 complex binds both tissue plasminogen activator (tPA) and plasminogen, enhancing tPA activation of plasminogen to generate plasmin (mimicking fibrin). Plasmin then cleaves ANGPTL4/8, releasing LPL from partial inhibition and restoring full LPL activity. This mechanism explains how postprandial adipose tissue achieves maximal LPL activity.","method":"Pulldown assays; in vitro plasmin generation assays; LPL activity assays with catalytically inactive plasminogen mutant (S760A) and PAI-1 controls","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 — reconstituted biochemical system with rigorous mutagenesis controls and multiple orthogonal methods","pmids":["36763533"],"is_preprint":false},{"year":2023,"finding":"ANGPTL4/8-mediated plasmin generation in adipose tissue selectively blocks inhibition of LPL by ANGPTL3/8 (via cleavage of ANGPTL3 within the ANGPTL3/8 complex), and also reduces inhibition by ANGPTL4, ANGPTL3, and ApoC3, while leaving ApoC2-mediated LPL stimulation unaffected. ANGPTL3/8 potently inhibits GPIHBP1-bound LPL activity.","method":"Recombinant protein LPL inhibition assays; functional assays with tPA + plasminogen system; GPIHBP1-LPL enzymatic activity assays","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — reconstituted biochemical system with specific controls for each inhibitor, mechanistically coherent","pmids":["37666362"],"is_preprint":false},{"year":2017,"finding":"The LPL S447X gain-of-function truncation (removing 2 C-terminal amino acids) does not increase specific enzymatic activity on synthetic or natural substrates, nor does it alter ANGPTL4 inhibition kinetics. However, LPLS447X enhances lipoprotein particle uptake to a greater degree than wild-type LPL, likely by exposing C-terminal residues implicated in binding lipoprotein uptake receptors.","method":"Purified recombinant LPLS447X and LPL dimer comparison; in vitro enzymatic assays; fluorescent lipoprotein uptake assays; LPL structural modeling","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — comprehensive purified protein biochemistry with multiple assay modalities","pmids":["27984852"],"is_preprint":false},{"year":2010,"finding":"Adiponectin increases LPL translocation to the cardiomyocyte cell surface via RhoA/ROCK-mediated actin cytoskeleton remodeling. Adiponectin stimulates RhoA activity, increases stress fiber formation, inhibits cofilin (reducing actin treadmilling), and this cytoskeletal remodeling is required for LPL translocation and subsequent heparin-releasable LPL activity.","method":"Primary adult rat cardiomyocytes; G-LISA RhoA activation assay; rhodamine-phalloidin immunofluorescence; immunofluorescence detection of surface LPL; heparin-releasable LPL activity assay; RhoA/ROCK inhibitor experiments","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in primary cells, single laboratory","pmids":["21147877"],"is_preprint":false},{"year":2005,"finding":"Beta-agonist isoproterenol increases cardiac LPL activity at the coronary lumen only during conditions of increased cardiac workload, and this effect is associated with AMPK activation and ACC280 inactivation. Simply switching from Langendorff to working heart conditions (increased afterload) induces AMPK/ACC280 phosphorylation and enhanced heparin-releasable LPL activity.","method":"In vivo isoproterenol treatment; Langendorff and isolated working heart preparations; AMPK and ACC280 phosphorylation assays; heparin-releasable LPL activity measurements","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo experiments linking AMPK signaling to LPL mobilization, single laboratory","pmids":["15687106"],"is_preprint":false},{"year":2004,"finding":"Palmitoyl lysophosphatidylcholine (PLPC) maintains high coronary luminal LPL activity via PKC-epsilon activation in endothelial cells. PLPC is metabolized via phospholipase D to lysophosphatidic acid (LPA), which then mobilizes LPL from cardiomyocytes. PKC activation is essential for this LPL recruitment.","method":"Isolated heart perfusion; PKC inhibitor (calphostin) experiments; endothelial cell PKC activation assays; exogenous PLD experiments with myocytes; LPL activity measurements","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection in intact organ and cell systems, single laboratory","pmids":["15522270"],"is_preprint":false},{"year":2014,"finding":"Endothelial cells respond to hyperglycemia by increasing GPIHBP1 expression, which enhances LPL shuttling across endothelial monolayers. Heparanase promotes GPIHBP1 expression by releasing PDGF from heparan sulfate proteoglycans, revealing a heparanase-PDGF-GPIHBP1 axis that regulates LPL-mediated fatty acid delivery to cardiomyocytes in the diabetic heart.","method":"Streptozotocin diabetic mouse model; in vitro endothelial cell glucose exposure; GPIHBP1 gene/protein expression; LPL transcytosis assay across endothelial monolayers; heparanase inhibition experiments","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro experiments with mechanistic dissection, single laboratory","pmids":["24735886"],"is_preprint":false},{"year":2016,"finding":"Monoclonal antibodies against the Ly6 domain of GPIHBP1 (RE3, RG3) abolish LPL binding, while an antibody against the acidic domain (RF4) does not, demonstrating that GPIHBP1's Ly6 domain is specifically required for LPL binding. A Ly6 domain missense mutation (W109S) reduces antibody affinity and abolishes LPL binding.","method":"Monoclonal antibody generation; LPL binding assays with domain-specific antibodies; W109S GPIHBP1 mutant binding analysis","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — functional antibody domain mapping with mutagenesis validation","pmids":["27875259"],"is_preprint":false},{"year":2017,"finding":"A conserved cysteine mutation in GPIHBP1 (p.C63Y) abolishes LPL binding and causes severe chylomicronemia in vivo. The mutant GPIHBP1 reaches the endothelial cell surface but at ~70% lower levels than wild-type, and the protein is predominantly monomeric, demonstrating that cysteine-mediated structure of GPIHBP1's Ly6 domain is essential for LPL capture.","method":"Knock-in mouse model (GPIHBP1 p.C63Y); immunohistochemistry; plasma TG measurements; Western blot analysis of GPIHBP1 oligomeric state","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo knock-in mouse with structural and functional analysis","pmids":["28476858"],"is_preprint":false},{"year":2015,"finding":"STAT3, constitutively activated in CLL cells, drives aberrant LPL expression by binding to the LPL promoter. Chromatin immunoprecipitation confirmed STAT3 occupancy at the LPL promoter; luciferase reporter assays demonstrated STAT3 activates the LPL promoter; STAT3-shRNA knockdown reduced LPL transcripts and protein. LPL-mediated triglyceride hydrolysis provides free fatty acids that CLL cells oxidize for energy.","method":"Luciferase reporter assays; chromatin immunoprecipitation; STAT3-shRNA knockdown; LPL-siRNA knockdown; fatty acid oxidation assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, reporter, KD) establishing STAT3→LPL transcriptional axis","pmids":["25733697"],"is_preprint":false},{"year":2018,"finding":"LPL yield can be dramatically enhanced by co-expressing its maturation factor LMF1, and by introducing furin-resistance mutations (including an N-linked glycan addition at the furin cleavage site), without adversely altering LPL enzymatic activity, stability, or in vivo function.","method":"Recombinant protein expression in HEK cells; LPL enzymatic activity assays; stability measurements; in vivo lipid measurements","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1 — biochemical characterization of modified LPL with activity and stability validation","pmids":["30318473"],"is_preprint":false},{"year":2021,"finding":"LPL expression in cardiomyocytes increases during myocardial infarction. Cardiomyocyte-specific LPL deficiency enhanced cardiac dysfunction and apoptosis after MI. LPL-derived glycerol is taken up via aquaporin 7 (AQP7) and converted by GPD2 to support ATP synthesis during ischemia, revealing an LPL/AQP7/GPD2 glycerol metabolic axis that protects the ischemic heart.","method":"Cardiomyocyte-specific LPL knockout mice; AQP7 and GPD2 knockout mice; MI model; cardiac function measurements; metabolic flux analyses","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — multiple genetic KO models with defined metabolic and functional readouts","pmids":["34807469"],"is_preprint":false},{"year":2021,"finding":"Apolipoprotein E (ApoE) content on VLDL inversely correlates with LPL-mediated TG hydrolysis rate. Exogenous APOE inhibits LPL lipolysis in a dose-dependent manner; APOE3 and especially APOE4 isoforms are effective LPL inhibitors, whereas APOE2 is not. This implicates VLDL-associated APOE as a physiological modulator of LPL activity.","method":"Novel in vitro LPL hydrolysis assay mimicking human plasma conditions; VLDL from 15 normolipidemic donors; mass spectrometry lipoprotein proteomics; exogenous APOE addition experiments","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro reconstitution with purified components and isoform-specific analysis","pmids":["34863862"],"is_preprint":false},{"year":2021,"finding":"Fasting decreases LPL activity in human adipose tissue by ~60% without changing LPL mRNA or protein levels, concurrent with increased ANGPTL4 mRNA (+90%) and protein (+46%). Insulin downregulates ANGPTL4 in primary human adipocytes while cortisol and fatty acids upregulate it, establishing the mechanism by which fasting reduces adipose LPL activity via ANGPTL4 induction.","method":"Human adipose tissue biopsies (fasted vs. fed); LPL activity assays; ANGPTL4/LPL mRNA and protein measurements; primary human adipocyte cell culture with insulin and cortisol treatment","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — human tissue with mechanistic follow-up in primary cells, single study","pmids":["32504883"],"is_preprint":false},{"year":2019,"finding":"ApoC-III inhibition (via antisense oligonucleotide) lowers plasma TG in mice lacking apoE and functional syndecan-1 by increasing LPL activity in white adipose tissue (not by improving hepatic TRL clearance), demonstrating that apoE determines the dominant mechanism of apoC-III action: with apoE, apoC-III primarily inhibits receptor-mediated TRL clearance; without apoE, apoC-III instead inhibits tissue LPL activity.","method":"ApoC-III ASO treatment in Apoe-/-Ndst1f/fAlb-Cre+ mice; LPL activity measurements in white adipose tissue; VLDL production and TRL clearance assays","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mouse model with specific metabolic readouts, single laboratory","pmids":["31092690"],"is_preprint":false},{"year":2006,"finding":"LPL-mediated lipolysis of VLDL in endothelial cells induces upregulation of AU-rich mRNAs (IL-8, ESM-1, VCAM-1, GM-CSF, TNF-alpha) and activates HuR (an AU-rich mRNA stabilizing protein) by increasing its polysomal localization. The free fatty acids and lipoprotein remnants generated by LPL activity mediate these downstream gene expression changes.","method":"cDNA subtraction; porcine aortic endothelial cell culture with LPL + VLDL; HuR polysomal localization assay; qPCR gene expression","journal":"Atherosclerosis","confidence":"Low","confidence_rationale":"Tier 3 — single laboratory, single method for mechanism (cDNA subtraction/expression), limited functional follow-up","pmids":["16494882"],"is_preprint":false},{"year":2024,"finding":"LPL regulation involves an extensive macromolecular interaction network: LPL oligomeric state (monomer/dimer) is central to its regulation, with dimeric LPL being the active form; multiple inhibitors (ANGPTL3/8, ANGPTL4, ApoC-III) and activators (ApoC-II, GPIHBP1) modulate activity through direct protein-protein interactions; and GPIHBP1 binding dramatically stabilizes LPL (Tm increases from ~35°C to ~58°C).","method":"Review synthesizing biophysical, structural, and biochemical studies including thermal stability measurements","journal":"Sub-cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 — synthesis of biophysical measurements including experimentally determined Tm values","pmids":["38963487"],"is_preprint":false},{"year":2019,"finding":"ZHX2 inhibits lipid uptake in hepatocellular carcinoma cells through transcriptional repression of LPL. ZHX2 overexpression reduced LPL mRNA and protein; LPL overexpression reversed ZHX2-mediated inhibition of lipid accumulation and cell proliferation, establishing a ZHX2→LPL transcriptional regulatory axis in NAFLD-HCC progression.","method":"ZHX2 overexpression and KO in HCC cell lines; xenograft mouse models; luciferase reporter assays; ChIP; IHC in patient samples","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — multiple experimental approaches (reporter, ChIP, rescue experiments) in cell lines and mouse models","pmids":["31740790"],"is_preprint":false},{"year":2021,"finding":"An expression system co-transfecting Drosophila Schneider 2 cells with human LPL, LMF1, and soluble GPIHBP1 yielded 4–28 mg/L of pure active LPL. Heparin-Sepharose purification disrupted the LPL-GPIHBP1 complex. Active-site mutant S132A, lipid-binding mutant W390A-W393A-W394A, and furin-resistant R297A were all successfully purified, enabling biochemical characterization of LPL's functional residues.","method":"Recombinant protein expression in Drosophila S2 cells; heparin affinity chromatography; LPL activity assays; site-directed mutagenesis","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1 — production and functional characterization of multiple site-directed LPL mutants","pmids":["34780727"],"is_preprint":false}],"current_model":"LPL is a triglyceride hydrolase that acts at the capillary lumen, where it is transported from subendothelial interstitial spaces to GPIHBP1 on endothelial cells (GPIHBP1 binding dramatically stabilizes LPL and is essential for TRL margination); LPL activity is tuned by a complex regulatory network including activators (ApoC-II) and inhibitors (ANGPTL3/8, ANGPTL4, ApoC-III acting on the lid domain), by postprandial plasmin-mediated cleavage of ANGPTL4/8 that restores maximal LPL activity in adipose tissue, and by ApoA5 which suppresses ANGPTL3/8-mediated inhibition; beyond hydrolysis, LPL exerts non-catalytic functions including receptor-bridging for lipoprotein particle uptake, regulation of insulin secretion in islets, and promotion of selective cholesterol ester uptake, while its secretion depends on LMF1 and Sel1L-mediated ER quality control."},"narrative":{"teleology":[{"year":1985,"claim":"Establishing that ApoC-III is a direct non-competitive inhibitor of LPL resolved how apolipoprotein composition of TRL particles modulates lipolysis rate.","evidence":"In vitro kinetic analysis of LPL-mediated VLDL hydrolysis with purified ApoC-III-2","pmids":["3973011"],"confidence":"High","gaps":["Binding site of ApoC-III on LPL was not mapped","In vivo contribution of ApoC-III to LPL inhibition vs. receptor-mediated clearance was unresolved"]},{"year":1987,"claim":"Cloning and sequencing of LPL cDNA placed the enzyme within a lipase gene family and provided the molecular tools for all subsequent structure-function studies.","evidence":"cDNA cloning and sequencing from human adipose tissue library","pmids":["3823907"],"confidence":"High","gaps":["No three-dimensional structure was available","Catalytic residues and domain boundaries were inferred by homology, not experimentally defined"]},{"year":1999,"claim":"Discovery that LPL expression in pancreatic islets negatively regulates insulin secretion revealed an unexpected extrahepatic, extra-adipose metabolic role for LPL.","evidence":"Gain- and loss-of-function experiments in INS-1 cells and LPL-deficient mouse islets with insulin secretion readouts","pmids":["10488074"],"confidence":"High","gaps":["Molecular mechanism linking LPL activity to suppression of insulin secretion was not defined","Relative contribution of lipolytic products vs. bridging function in islets was unknown"]},{"year":2001,"claim":"Demonstrating that catalytically inactive LPL suffices for selective cholesteryl ester uptake separated LPL's non-catalytic bridging function from its hydrolytic activity, establishing dual functional modes.","evidence":"Transgenic mice expressing catalytically inactive LPL on LPL-null background with radiolabeled lipoprotein uptake assays","pmids":["11751882"],"confidence":"High","gaps":["Identity of receptors engaged by LPL bridging was not established","Structural basis for bridging vs. catalytic function was unknown"]},{"year":2014,"claim":"Identification of GPIHBP1 as the obligate endothelial platform for LPL-mediated TRL margination resolved how LPL reaches the capillary lumen and why HSPG-bound LPL alone is insufficient for intravascular lipolysis.","evidence":"Fluorescence microscopy, IR-labeled lipoprotein margination assays, and EM tomography in wild-type and Gpihbp1−/− mice","pmids":["24726386"],"confidence":"High","gaps":["Structural details of LPL–GPIHBP1 interaction were not resolved","How GPIHBP1 stabilizes LPL at the molecular level was unknown"]},{"year":2014,"claim":"Discovery that Sel1L physically interacts with LPL-LMF1 and is required for LPL ER exit defined the ER quality control pathway governing LPL biogenesis, explaining how misfolded LPL is triaged to autophagy.","evidence":"Adipocyte-specific Sel1L knockout mice, co-immunoprecipitation, ER fractionation, autophagy inhibition","pmids":["25066055"],"confidence":"High","gaps":["Whether Sel1L acts directly on LPL folding or on LMF1-LPL complex stability was unclear","Contribution of proteasomal vs. autophagic degradation under physiological conditions was not quantified"]},{"year":2016,"claim":"Mapping GPIHBP1's Ly6 domain as the LPL-binding domain and showing that HSPG-bound LPL actively migrates to GPIHBP1 explained the directional transport of LPL from parenchymal cells to the capillary endothelium.","evidence":"GPIHBP1-coated agarose beads in Gpihbp1−/− adipose tissue; Ly6 domain W109S mutagenesis; monoclonal antibody domain mapping","pmids":["27811232","27875259"],"confidence":"High","gaps":["Kinetics of LPL transfer from HSPGs to GPIHBP1 in vivo were not quantified","Role of GPIHBP1 acidic domain in LPL stabilization vs. transport was not fully resolved"]},{"year":2017,"claim":"Characterizing the LPL S447X gain-of-function variant showed it does not increase intrinsic enzymatic activity but instead enhances non-catalytic lipoprotein uptake, clarifying the mechanistic basis of a clinically important human variant.","evidence":"Purified recombinant LPLS447X vs. wild-type enzymatic, ANGPTL4 inhibition, and fluorescent lipoprotein uptake assays","pmids":["27984852"],"confidence":"High","gaps":["Receptor(s) engaged by the exposed C-terminal region were not identified","In vivo significance of the enhanced uptake function was not directly tested"]},{"year":2018,"claim":"HDX-MS mapping of ANGPTL4 binding to LPL's active-site lid domain provided the first structural explanation for how ANGPTL4 inhibits LPL catalysis by occluding substrate access.","evidence":"Hydrogen-deuterium exchange mass spectrometry, chimeric LPL variants, LPL peptide mimetics, in vitro inhibition assays","pmids":["30591589"],"confidence":"High","gaps":["Whether ANGPTL4 also destabilizes the LPL dimer through lid-domain binding was not resolved","ANGPTL3/8 binding site on LPL had not been comparably mapped"]},{"year":2021,"claim":"Demonstrating that ApoA5 lowers triglycerides by specifically blocking ANGPTL3/8-mediated LPL inhibition—rather than directly activating LPL—placed ApoA5 within the ANGPTL regulatory network as a selective counter-inhibitor.","evidence":"Immunoprecipitation-mass spectrometry of human serum, biolayer interferometry, functional LPL enzymatic assays","pmids":["33762177"],"confidence":"High","gaps":["Structural basis of ApoA5–ANGPTL3/8 interaction was unknown at the time","In vivo tissue-specific contribution of ApoA5 to LPL derepression was not established"]},{"year":2022,"claim":"Mapping the shared LPL/ApoA5 binding epitope on the ANGPTL3/8 leucine-zipper interface revealed how two endogenous regulators compete for the same inhibitory complex and provided a therapeutic antibody target.","evidence":"HDX-MS on ANGPTL3/8; biolayer interferometry; anti-ANGPTL3/8 antibody lowered TG in vivo","pmids":["35307397"],"confidence":"High","gaps":["Relative affinity of LPL vs. ApoA5 for ANGPTL3/8 in physiological conditions was not quantified","Whether this epitope is accessible on GPIHBP1-bound LPL in vivo was not addressed"]},{"year":2023,"claim":"Discovery that ANGPTL4/8 acts as a plasminogen activation scaffold—generating plasmin that cleaves inhibitory ANGPTL complexes to restore LPL activity—provided a feedforward mechanism for postprandial adipose lipolysis.","evidence":"Reconstituted in vitro tPA-plasminogen-ANGPTL4/8 system with catalytically inactive plasminogen and PAI-1 controls; LPL activity assays","pmids":["36763533","37666362"],"confidence":"High","gaps":["In vivo validation that plasmin generation at adipose capillaries is the dominant mechanism for postprandial LPL reactivation is lacking","Whether plasmin also cleaves GPIHBP1-bound ANGPTL complexes in situ was not determined"]},{"year":null,"claim":"The full structural basis of LPL dimer-to-monomer transition during ANGPTL-mediated inactivation, the identity of receptors that mediate LPL's non-catalytic bridging uptake, and the in vivo significance of LPL regulation by ApoE isoforms remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["High-resolution structure of ANGPTL4-bound or ANGPTL3/8-bound LPL has not been determined","Receptors mediating LPL bridging function are unidentified","In vivo role of ApoE isoform-specific LPL inhibition in human lipoprotein metabolism is not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,2,3,9,14]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,30]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,4,7,8]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,7,15]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,3,9,12,13,25]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[2,4,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,11,25]}],"complexes":["LPL homodimer","LPL-GPIHBP1 complex","LPL-LMF1-Sel1L maturation complex"],"partners":["GPIHBP1","LMF1","SEL1L","APOC3","ANGPTL4","ANGPTL3","ANGPTL8","APOA5"],"other_free_text":[]},"mechanistic_narrative":"LPL is a secreted triglyceride hydrolase that cleaves the triacylglycerol core of chylomicrons and VLDL at the capillary lumen, delivering free fatty acids and monoacylglycerol to tissues; it also exerts non-catalytic functions including receptor-bridging for lipoprotein particle uptake and selective cholesteryl ester uptake independent of its catalytic activity [PMID:12483461, PMID:11751882]. LPL is active as a homodimer, requires the ER chaperone LMF1 and the Sel1L-dependent ERAD pathway for proper folding and secretion, and is transported from subendothelial heparan sulfate proteoglycans to the endothelial surface by GPIHBP1, whose Ly6 domain is essential for LPL binding and which dramatically stabilizes LPL and is required for triglyceride-rich lipoprotein margination [PMID:24726386, PMID:25066055, PMID:27811232]. LPL activity is tuned by a network of protein regulators—activated by ApoC-II, inhibited by ANGPTL4 (which targets the active-site lid domain), ANGPTL3/8, and ApoC-III, with ApoA5 selectively blocking ANGPTL3/8-mediated inhibition—and postprandial restoration of adipose LPL activity is achieved through plasmin-mediated cleavage of inhibitory ANGPTL complexes [PMID:30591589, PMID:33762177, PMID:36763533, PMID:32504883]. Beyond lipolysis, LPL regulates insulin secretion in pancreatic islets and provides glycerol that supports cardiac ATP synthesis during ischemia via an AQP7/GPD2 metabolic axis [PMID:10488074, PMID:34807469]."},"prefetch_data":{"uniprot":{"accession":"P06858","full_name":"Lipoprotein lipase","aliases":["Phospholipase A1"],"length_aa":475,"mass_kda":53.2,"function":"Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage (PubMed:11342582, PubMed:27578112, PubMed:8675619). Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity (PubMed:12032167, PubMed:7592706). Mediates margination of triglyceride-rich lipoprotein particles in capillaries (PubMed:24726386). Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans (PubMed:11342582, PubMed:27811232)","subcellular_location":"Cell membrane; Secreted; Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P06858/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LPL","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LPL","total_profiled":1310},"omim":[{"mim_id":"619324","title":"HYPERTRIGLYCERIDEMIA 2; HYTG2","url":"https://www.omim.org/entry/619324"},{"mim_id":"617347","title":"HYPERLIPOPROTEINEMIA, TYPE III","url":"https://www.omim.org/entry/617347"},{"mim_id":"616223","title":"ANGIOPOIETIN-LIKE 8; ANGPTL8","url":"https://www.omim.org/entry/616223"},{"mim_id":"615947","title":"HYPERLIPOPROTEINEMIA, TYPE ID","url":"https://www.omim.org/entry/615947"},{"mim_id":"615881","title":"PLASMA TRIGLYCERIDE LEVEL QUANTITATIVE TRAIT LOCUS; TGQTL","url":"https://www.omim.org/entry/615881"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":880.1},{"tissue":"heart muscle","ntpm":327.9}],"url":"https://www.proteinatlas.org/search/LPL"},"hgnc":{"alias_symbol":[],"prev_symbol":["LIPD"]},"alphafold":{"accession":"P06858","domains":[{"cath_id":"3.40.50.1820","chopping":"27-329","consensus_level":"high","plddt":93.5943,"start":27,"end":329},{"cath_id":"2.60.60.20","chopping":"341-468","consensus_level":"high","plddt":94.2768,"start":341,"end":468}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P06858","model_url":"https://alphafold.ebi.ac.uk/files/AF-P06858-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P06858-F1-predicted_aligned_error_v6.png","plddt_mean":91.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LPL","jax_strain_url":"https://www.jax.org/strain/search?query=LPL"},"sequence":{"accession":"P06858","fasta_url":"https://rest.uniprot.org/uniprotkb/P06858.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P06858/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P06858"}},"corpus_meta":[{"pmid":"30694319","id":"PMC_30694319","title":"Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.","date":"2019","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/30694319","citation_count":507,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26934567","id":"PMC_26934567","title":"Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.","date":"2016","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26934567","citation_count":412,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22239554","id":"PMC_22239554","title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.","date":"2012","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22239554","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16894240","id":"PMC_16894240","title":"The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16894240","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24726386","id":"PMC_24726386","title":"The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries.","date":"2014","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24726386","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25066055","id":"PMC_25066055","title":"The ER-associated degradation adaptor protein Sel1L regulates LPL secretion and lipid metabolism.","date":"2014","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25066055","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21943158","id":"PMC_21943158","title":"Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits.","date":"2011","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21943158","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7592412","id":"PMC_7592412","title":"The three genes lipB, lipC, and lipD involved in the extracellular secretion of the Serratia marcescens lipase which lacks an N-terminal signal peptide.","date":"1995","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/7592412","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11751882","id":"PMC_11751882","title":"Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11751882","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15979095","id":"PMC_15979095","title":"Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR-alpha, PPAR-gamma, and LPL mRNA expressions.","date":"2005","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15979095","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8049185","id":"PMC_8049185","title":"Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia.","date":"1994","source":"Arteriosclerosis and thrombosis : a journal of vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8049185","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25733697","id":"PMC_25733697","title":"Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25733697","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34803493","id":"PMC_34803493","title":"Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34803493","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33762177","id":"PMC_33762177","title":"ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/33762177","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"167258","id":"PMC_167258","title":"Lipd profiles of plasma lipoproteins of fasted and fed normal and choline-deficient rats.","date":"1975","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/167258","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19295657","id":"PMC_19295657","title":"Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review.","date":"2009","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19295657","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17600746","id":"PMC_17600746","title":"Insulin regulation of lipoprotein lipase (LPL) activity and expression in gilthead sea bream (Sparus aurata).","date":"2007","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17600746","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25966443","id":"PMC_25966443","title":"Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25966443","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15353045","id":"PMC_15353045","title":"Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.","date":"2004","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15353045","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10488074","id":"PMC_10488074","title":"Relative hypoglycemia and hyperinsulinemia in mice with heterozygous lipoprotein lipase (LPL) deficiency. Islet LPL regulates insulin secretion.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10488074","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32504883","id":"PMC_32504883","title":"Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32504883","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31740790","id":"PMC_31740790","title":"Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31740790","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27206919","id":"PMC_27206919","title":"Effect of Low-Power Laser (LPL) and Light-Emitting Diode (LED) on Inflammatory Response in Burn Wound Healing.","date":"2016","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27206919","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31092690","id":"PMC_31092690","title":"ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/31092690","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28694296","id":"PMC_28694296","title":"Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.","date":"2017","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/28694296","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12208477","id":"PMC_12208477","title":"Effect of gender on phenotypic expression of the S447X mutation in LPL: the Copenhagen City Heart Study.","date":"2002","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/12208477","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26503844","id":"PMC_26503844","title":"CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26503844","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35307397","id":"PMC_35307397","title":"An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif.","date":"2022","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/35307397","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27055971","id":"PMC_27055971","title":"Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency.","date":"2015","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/27055971","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9672079","id":"PMC_9672079","title":"Inhibition of LPL expression in human monocyte-derived macrophages is dependent on LDL oxidation state: a key role for lysophosphatidylcholine.","date":"1998","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9672079","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27811232","id":"PMC_27811232","title":"Mobility of \"HSPG-bound\" LPL explains how LPL is able to reach GPIHBP1 on capillaries.","date":"2016","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/27811232","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18367731","id":"PMC_18367731","title":"The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18367731","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30591589","id":"PMC_30591589","title":"Mapping the sites of the lipoprotein lipase (LPL)-angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30591589","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12690214","id":"PMC_12690214","title":"Lipoprotein lipase (LPL) gene variation and progression of carotid artery plaque.","date":"2003","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/12690214","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29794473","id":"PMC_29794473","title":"MiR-27b Impairs Adipocyte Differentiation of Human Adipose Tissue-Derived Mesenchymal Stem Cells by Targeting LPL.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29794473","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19004026","id":"PMC_19004026","title":"Genetic and epigenetic inactivation of LPL gene in human prostate cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19004026","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31434492","id":"PMC_31434492","title":"Role of LpL (Lipoprotein Lipase) in Macrophage Polarization In Vitro and In Vivo.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31434492","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21147877","id":"PMC_21147877","title":"Adiponectin increases LPL activity via RhoA/ROCK-mediated actin remodelling in adult rat cardiomyocytes.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21147877","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25635326","id":"PMC_25635326","title":"Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25635326","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27578112","id":"PMC_27578112","title":"Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia.","date":"2016","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/27578112","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24309104","id":"PMC_24309104","title":"The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24309104","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17311894","id":"PMC_17311894","title":"Sex differences in abdominal, gluteal, and thigh LPL activity.","date":"2007","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17311894","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20011054","id":"PMC_20011054","title":"Effects of Glycyrrhizic Acid on Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma), Lipoprotein Lipase (LPL), Serum Lipid and HOMA-IR in Rats.","date":"2010","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/20011054","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19018513","id":"PMC_19018513","title":"The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits.","date":"2008","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19018513","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15687106","id":"PMC_15687106","title":"beta-Agonist stimulation produces changes in cardiac AMPK and coronary lumen LPL only during increased workload.","date":"2005","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15687106","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37119902","id":"PMC_37119902","title":"miR-128-3p regulates chicken granulosa cell function via 14-3-3β/FoxO and PPAR-γ/LPL signaling pathways.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37119902","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19403283","id":"PMC_19403283","title":"APOE, CETP and LPL genes show strong association with lipid levels in Greek children.","date":"2009","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/19403283","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29046332","id":"PMC_29046332","title":"Adipose Tissue LPL Methylation is Associated with Triglyceride Concentrations in the Metabolic Syndrome.","date":"2017","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29046332","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12687649","id":"PMC_12687649","title":"Association between lipoprotein lipase (LPL) gene and blood lipids: a common variant for a common trait?","date":"2003","source":"Genetic epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/12687649","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24232385","id":"PMC_24232385","title":"Molecular characterization of oxidative stress-inducible LipD of Mycobacterium tuberculosis H37Rv.","date":"2014","source":"Current microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24232385","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36476373","id":"PMC_36476373","title":"The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants.","date":"2022","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/36476373","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12641539","id":"PMC_12641539","title":"Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis.","date":"2003","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12641539","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36763533","id":"PMC_36763533","title":"Angiopoietin-like protein 4/8 complex-mediated plasmin generation leads to cleavage of the complex and restoration of LPL activity.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36763533","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32739175","id":"PMC_32739175","title":"Artesunate inhibits atherosclerosis by upregulating vascular smooth muscle cells-derived LPL expression via the KLF2/NRF2/TCF7L2 pathway.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32739175","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27984852","id":"PMC_27984852","title":"Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPLS447X, Reveals Increased Lipoprotein Uptake.","date":"2017","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27984852","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29229543","id":"PMC_29229543","title":"The complete genome sequence of Lactobacillus plantarum LPL-1, a novel antibacterial probiotic producing class IIa bacteriocin.","date":"2017","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29229543","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30703449","id":"PMC_30703449","title":"MicroRNA-224 impairs adipogenic differentiation of bovine preadipocytes by targeting LPL.","date":"2019","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/30703449","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25612068","id":"PMC_25612068","title":"High adipose LPL activity and adipocyte hypertrophy reduce visceral fat and metabolic risk in obese, older women.","date":"2015","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25612068","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34807469","id":"PMC_34807469","title":"LPL/AQP7/GPD2 promotes glycerol metabolism under hypoxia and prevents cardiac dysfunction during ischemia.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34807469","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26148147","id":"PMC_26148147","title":"Regional distribution of body fat in relation to DNA methylation within the LPL, ADIPOQ and PPARγ promoters in subcutaneous adipose tissue.","date":"2015","source":"Nutrition & diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26148147","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28867683","id":"PMC_28867683","title":"MicroRNA-134 Promotes the Development of Atherosclerosis Via the ANGPTL4/LPL Pathway in Apolipoprotein E Knockout Mice.","date":"2017","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/28867683","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28392937","id":"PMC_28392937","title":"Reduced LPL and subcutaneous lipid storage capacity are associated with metabolic syndrome in postmenopausal women with obesity.","date":"2016","source":"Obesity science & practice","url":"https://pubmed.ncbi.nlm.nih.gov/28392937","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24703657","id":"PMC_24703657","title":"A novel Lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4).","date":"2014","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24703657","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20410100","id":"PMC_20410100","title":"Genetic variation in APOJ, LPL, and TNFRSF10B affects plasma fatty acid distribution in Alaskan Eskimos.","date":"2010","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/20410100","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30096295","id":"PMC_30096295","title":"Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30096295","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39392008","id":"PMC_39392008","title":"Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/39392008","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34863862","id":"PMC_34863862","title":"Apolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/34863862","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36064433","id":"PMC_36064433","title":"CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis.","date":"2022","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36064433","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28846595","id":"PMC_28846595","title":"Maternal Prenatal Folic Acid Supplementation Programs Offspring Lipid Metabolism by Aberrant DNA Methylation in Hepatic ATGL and Adipose LPL in Rats.","date":"2017","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/28846595","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19772655","id":"PMC_19772655","title":"Genetic association study of selected candidate genes (ApoB, LPL, Leptin) and telomere length in obese and hypertensive individuals.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19772655","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36596114","id":"PMC_36596114","title":"A novel and controllable method for simultaneous preparation of human milk fat substitutes (OPL, OPO and LPL): two-step enzymatic ethanolysis-esterification strategy.","date":"2022","source":"Food research international (Ottawa, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/36596114","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30471854","id":"PMC_30471854","title":"Nobiletin reduces LPL-mediated lipid accumulation and pro-inflammatory cytokine secretion through upregulation of miR-590 expression.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30471854","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31065241","id":"PMC_31065241","title":"A Novel Regulator of Preadipocyte Differentiation, Transcription Factor TCF21, Functions Partially Through Promoting LPL Expression.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31065241","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28083519","id":"PMC_28083519","title":"Staphylococcus aureus Lpl Lipoproteins Delay G2/M Phase Transition in HeLa Cells.","date":"2016","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28083519","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35242114","id":"PMC_35242114","title":"Synergistic Inhibition of Plantaricin E/F and Lactic Acid Against Aeromonas hydrophila LPL-1 Reveals the Novel Potential of Class IIb Bacteriocin.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35242114","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20836743","id":"PMC_20836743","title":"Variable effects of maternal and paternal-fetal contribution to the risk for preeclampsia combining GSTP1, eNOS, and LPL gene polymorphisms.","date":"2010","source":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","url":"https://pubmed.ncbi.nlm.nih.gov/20836743","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27875259","id":"PMC_27875259","title":"Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL.","date":"2016","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/27875259","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37666362","id":"PMC_37666362","title":"Decoding the role of angiopoietin-like protein 4/8 complex-mediated plasmin generation in the regulation of LPL activity.","date":"2023","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/37666362","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28476858","id":"PMC_28476858","title":"Mutating a conserved cysteine in GPIHBP1 reduces amounts of GPIHBP1 in capillaries and abolishes LPL binding.","date":"2017","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/28476858","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34606535","id":"PMC_34606535","title":"MicroRNA-432 inhibits milk fat synthesis by targeting SCD and LPL in ovine mammary epithelial cells.","date":"2021","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/34606535","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35537114","id":"PMC_35537114","title":"Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35537114","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24735886","id":"PMC_24735886","title":"Endothelial cells respond to hyperglycemia by increasing the LPL transporter GPIHBP1.","date":"2014","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24735886","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26342331","id":"PMC_26342331","title":"Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): a reappraisal by using a resequencing approach.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26342331","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27913180","id":"PMC_27913180","title":"Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator.","date":"2016","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27913180","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17328917","id":"PMC_17328917","title":"Polymorphism of apolipoprotein E (APOE) and lipoprotein lipase (LPL) genes and ischaemic stroke in individuals of Yakut ethnicity.","date":"2007","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17328917","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19804633","id":"PMC_19804633","title":"Variants of ESR1, APOE, LPL and IL-6 loci in young healthy subjects: association with lipid status and obesity.","date":"2009","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/19804633","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38963487","id":"PMC_38963487","title":"Macromolecular Interactions of Lipoprotein Lipase (LPL).","date":"2024","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38963487","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30925325","id":"PMC_30925325","title":"Resistin up-regulates LPL expression through the PPARγ-dependent PI3K/AKT signaling pathway impacting lipid accumulation in RAW264.7 macrophages.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/30925325","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18068174","id":"PMC_18068174","title":"Genetic screening of the LPL gene in hypertriglyceridaemic patients.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18068174","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32256662","id":"PMC_32256662","title":"Erchen Decoction Mitigates Lipid Metabolism Disorder by the Regulation of PPARγ and LPL Gene in a High-Fat Diet C57BL/6 Mice Model.","date":"2020","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/32256662","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15522270","id":"PMC_15522270","title":"Palmitoyl lysophosphatidylcholine mediated mobilization of LPL to the coronary luminal surface requires PKC activation.","date":"2004","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15522270","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22810051","id":"PMC_22810051","title":"Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.","date":"2012","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22810051","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16494882","id":"PMC_16494882","title":"LPL-mediated lipolysis of VLDL induces an upregulation of AU-rich mRNAs and an activation of HuR in endothelial cells.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16494882","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30318473","id":"PMC_30318473","title":"Coexpression of novel furin-resistant LPL variants with lipase maturation factor 1 enhances LPL secretion and activity.","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/30318473","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33599871","id":"PMC_33599871","title":"Association of NFκβ, TNFα, IL-6, IL-1β, and LPL Polymorphisms with Type 2 Diabetes Mellitus and Biochemical Parameters in a Mexican Population.","date":"2021","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33599871","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22342712","id":"PMC_22342712","title":"1,3,5,8-tetrahydroxyxanthone regulates ANGPTL3-LPL pathway to lessen the ketosis in mice.","date":"2012","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22342712","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11848498","id":"PMC_11848498","title":"Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction.","date":"2001","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11848498","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29104012","id":"PMC_29104012","title":"ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.","date":"2017","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29104012","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34780727","id":"PMC_34780727","title":"Expression and one-step purification of active LPL contemplated by biophysical considerations.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/34780727","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30685441","id":"PMC_30685441","title":"Deciphering the role of V200A and N291S mutations leading to LPL deficiency.","date":"2019","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/30685441","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20686565","id":"PMC_20686565","title":"Biological, clinical and population relevance of 95 loci for blood lipids.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20686565","citation_count":2873,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24097068","id":"PMC_24097068","title":"Discovery and refinement of loci associated with lipid levels.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24097068","citation_count":2409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17463246","id":"PMC_17463246","title":"Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.","date":"2007","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17463246","citation_count":2225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193043","id":"PMC_18193043","title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193043","citation_count":1310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18187620","id":"PMC_18187620","title":"Identification of host proteins required for HIV infection through a functional genomic screen.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18187620","citation_count":1165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193044","id":"PMC_18193044","title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193044","citation_count":1130,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060906","id":"PMC_19060906","title":"Common variants at 30 loci contribute to polygenic dyslipidemia.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060906","citation_count":1113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060911","id":"PMC_19060911","title":"Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060911","citation_count":695,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12483461","id":"PMC_12483461","title":"Lipoprotein lipase: structure, function, regulation, and role in disease.","date":"2002","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/12483461","citation_count":630,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060910","id":"PMC_19060910","title":"Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060910","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18354102","id":"PMC_18354102","title":"Polymorphisms associated with cholesterol and risk of cardiovascular events.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18354102","citation_count":530,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3823907","id":"PMC_3823907","title":"Human lipoprotein lipase complementary DNA sequence.","date":"1987","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/3823907","citation_count":482,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22286219","id":"PMC_22286219","title":"Genome-wide association study identifies multiple loci influencing human serum metabolite levels.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22286219","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20385819","id":"PMC_20385819","title":"Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20385819","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20139978","id":"PMC_20139978","title":"Genome-wide association study of hematological and biochemical traits in a Japanese population.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20139978","citation_count":406,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3973011","id":"PMC_3973011","title":"Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.","date":"1985","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/3973011","citation_count":399,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9662394","id":"PMC_9662394","title":"DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9662394","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19596235","id":"PMC_19596235","title":"Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19596235","citation_count":375,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18454146","id":"PMC_18454146","title":"Common genetic variation near MC4R is associated with waist circumference and insulin resistance.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18454146","citation_count":365,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20714348","id":"PMC_20714348","title":"Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits.","date":"2010","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20714348","citation_count":363,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20657596","id":"PMC_20657596","title":"Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20657596","citation_count":354,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54962,"output_tokens":8366,"usd":0.145188},"stage2":{"model":"claude-opus-4-6","input_tokens":12165,"output_tokens":5287,"usd":0.2895},"total_usd":0.81492,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":67828,"output_tokens":7880,"usd":0.160842},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11827,"output_tokens":3485,"usd":0.21939}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"GPIHBP1-bound LPL is the main determinant of triglyceride-rich lipoprotein (TRL) margination in heart capillaries; TRL margination requires LPL bound to GPIHBP1, not LPL bound to heparan sulfate proteoglycans (HSPGs).\",\n      \"method\": \"Fluorescence microscopy, quantitative IR-dye-labeled lipoprotein assays, EM tomography in wild-type vs Gpihbp1−/− mice; cell-culture and in vivo studies\",\n      \"journal\": \"Cell Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo and in vitro methods, clean KO with defined phenotype\",\n      \"pmids\": [\"24726386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sel1L physically interacts with and stabilizes the LPL–LMF1 maturation complex in the ER; in the absence of Sel1L, LPL is retained in the ER, forms aggregates, and is degraded by autophagy rather than secreted.\",\n      \"method\": \"Adipocyte-specific Sel1L knockout mice; co-immunoprecipitation; protein fractionation; autophagy inhibition assays; postprandial triglyceride measurements\",\n      \"journal\": \"Cell Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, clean tissue-specific KO with defined secretion phenotype, replicated across cell types\",\n      \"pmids\": [\"25066055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HSPG-bound LPL is mobile in interstitial spaces and can transfer to GPIHBP1 on endothelial cells; this transfer requires the Ly6 domain of GPIHBP1 (W109S mutation abolishes it) but not the acidic domain.\",\n      \"method\": \"Cultured cell transfer assays (LPL movement to soluble GPIHBP1, GPIHBP1-coated beads, GPIHBP1-expressing cells); in vivo injection of GPIHBP1-coated beads into GPIHBP1-deficient mouse adipose tissue; GPIHBP1 domain mutants\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal in vitro and in vivo methods, site-directed mutants validate mechanism\",\n      \"pmids\": [\"27811232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ApoC-III potently inhibits triglyceride hydrolysis by LPL when LPL is bound to GPIHBP1; the inhibitory effect is greater for GPIHBP1-bound LPL than for free LPL. A naturally occurring apoC-III variant (p.A23T) associated with low plasma triglycerides shows reduced capacity to inhibit both free and GPIHBP1-bound LPL.\",\n      \"method\": \"In vitro triglyceride hydrolysis assays with free vs GPIHBP1-bead-bound LPL; cell-based binding assays; use of apoC-III transgenic mouse TRLs and recombinant apoC-III; natural variant functional comparison\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted assays with multiple conditions, mutagenesis/variant validation\",\n      \"pmids\": [\"28694296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ANGPTL4 binds LPL at the lid domain (which covers the active site) and a nearby α-helix, inhibiting LPL by blocking substrate access to the active site; these binding sites were mapped by hydrogen-deuterium exchange MS and validated with chimeric LPL variants and an LPL peptide mimetic.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry; chimeric LPL variants; LPL peptide mimetic competition assays\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — HDX-MS structural mapping plus functional mutagenesis validation\",\n      \"pmids\": [\"30591589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoA5 lowers triglycerides by suppressing ANGPTL3/8-mediated LPL inhibition; ApoA5 associates with ANGPTL3/8 in human serum and has no direct effect on LPL activity, nor does it suppress ANGPTL3, ANGPTL4, or ANGPTL4/8 inhibition of LPL.\",\n      \"method\": \"Immunoprecipitation-MS, Western blotting, biolayer interferometry, functional LPL enzymatic assays, kinetic analyses\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal biochemical methods including in vitro LPL activity assays and binding measurements\",\n      \"pmids\": [\"33762177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LPL and ApoA5 both bind the same leucine zipper-like epitope on the ANGPTL3/8 complex (formed from N-terminal regions of ANGPTL3 and ANGPTL8 unmasked upon complex formation), explaining how ApoA5 competitively blocks ANGPTL3/8-mediated LPL inhibition; an antibody targeting this epitope potently inhibits ANGPTL3/8-mediated LPL inhibition in vitro and lowers TG in vivo.\",\n      \"method\": \"Hydrogen-deuterium exchange MS, molecular modeling, biolayer interferometry, in vitro LPL enzymatic assays, in vivo TG measurements in mice\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — HDX-MS structural mapping, binding assays, in vitro functional assays, in vivo confirmation\",\n      \"pmids\": [\"35307397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The ANGPTL4/8 complex binds both tissue plasminogen activator (tPA) and plasminogen, enhances tPA-mediated plasminogen-to-plasmin conversion (mimicking fibrin), and the resulting plasmin cleaves ANGPTL4/8, releasing LPL inhibition and restoring LPL activity postprandially in adipose tissue.\",\n      \"method\": \"Pulldown experiments; in vitro plasmin generation assays; catalytically inactive plasminogen mutant (S760A) and PAI-1 controls; LPL activity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted biochemical assays with multiple controls and catalytic-dead mutant validation\",\n      \"pmids\": [\"36763533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANGPTL4/8-generated plasmin also blocks ANGPTL3/8-, ANGPTL4-, ANGPTL3-, and ApoC3-mediated LPL inhibition (via cleavage of the ANGPTL3/8 complex fibrinogen-like domain) while leaving ApoC2-mediated LPL stimulation intact, enabling maximal postprandial LPL activity in adipose tissue.\",\n      \"method\": \"In vitro LPL activity assays with ANGPTL4/8 + tPA + plasminogen in the presence of various LPL inhibitors and ApoC2\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic assays with multiple inhibitor combinations\",\n      \"pmids\": [\"37666362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Catalytically inactive LPL alone (in the absence of active LPL in the same tissue) can mediate selective cholesterol ester uptake but cannot reduce plasma triglycerides or increase whole-particle lipoprotein uptake; active LPL is required for triglyceride hydrolysis and whole-particle uptake.\",\n      \"method\": \"Transgenic mice expressing catalytically inactive LPL (Mck-N-LPL) crossed onto LPL-deficient backgrounds; plasma TG measurements; radiolabeled lipoprotein uptake assays; muscle lipid droplet histology\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in multiple mouse cross backgrounds with defined metabolic phenotypes\",\n      \"pmids\": [\"11751882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The gain-of-function LPL variant S447X (LPLS447X) does not differ from wild-type LPL in specific enzymatic activity or ANGPTL4 inhibition kinetics, but enhances lipoprotein particle uptake to a greater degree than LPL; structural modeling suggests the truncation exposes residues involved in binding to lipoprotein uptake receptors.\",\n      \"method\": \"Purified LPL and LPLS447X dimer comparison; activity assays on synthetic and natural substrates; ANGPTL4 Ki measurement; fluorescently labeled lipoprotein uptake assays; structural modeling\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive in vitro biochemical comparison with purified proteins and multiple assays\",\n      \"pmids\": [\"27984852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Monoclonal antibodies against GPIHBP1's Ly6 domain (RE3, RG3) abolish LPL binding to GPIHBP1, while an antibody against GPIHBP1's acidic domain (RF4) does not; these antibodies also show reduced affinity to the W109S Ly6 domain mutant, confirming the Ly6 domain as the LPL-binding region.\",\n      \"method\": \"Monoclonal antibody panel development; LPL binding assays; GPIHBP1 Ly6 and acidic domain mutants; immunohistochemistry\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific antibodies and mutant validation with functional readout\",\n      \"pmids\": [\"27875259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A conserved cysteine mutation in GPIHBP1 (p.C63Y) abolishes GPIHBP1's ability to bind LPL in vivo, causing LPL mislocalization and severe chylomicronemia; the mutation reduces but does not eliminate GPIHBP1 on endothelial cell surfaces.\",\n      \"method\": \"Knock-in mouse model (p.C63Y); plasma TG measurement; immunohistochemistry for GPIHBP1 and LPL; CHO cell surface expression studies\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knock-in mouse model with defined functional and localization phenotype\",\n      \"pmids\": [\"28476858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"LPL is expressed in pancreatic islets and regulates insulin secretion: islet LPL suppresses insulin secretion, as shown by increased secretion from LPL+/− and LPL−/− islets vs LPL+/+ islets; gain of LPL activity (via AAV) reduced insulin secretion from INS-1 cells, while loss of LPL activity (antisense oligonucleotide) increased secretion.\",\n      \"method\": \"Heterozygous LPL-deficient mice; isolated islet secretion assays; adeno-associated virus LPL overexpression and antisense oligonucleotide knockdown in INS-1 cells; hyperinsulinemic clamp\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function experiments in islets and INS-1 cells with defined secretion phenotype\",\n      \"pmids\": [\"10488074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Adiponectin increases LPL translocation to the cardiomyocyte cell surface via RhoA/ROCK-mediated actin remodeling; adiponectin activates RhoA, promotes stress fiber formation, inhibits cofilin (reducing actin treadmilling), and this cytoskeletal remodeling is required for plasma membrane LPL accumulation and subsequent LPL activity.\",\n      \"method\": \"Primary adult rat cardiomyocytes; G-LISA RhoA activation assay; rhodamine-phalloidin F/G-actin ratio; RhoA and ROCK inhibitors; immunofluorescence LPL surface detection; heparin-releasable LPL activity assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal cell biology and biochemical assays with pharmacological inhibitor validation\",\n      \"pmids\": [\"21147877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"β-agonist (isoproterenol) increases coronary luminal LPL activity only during conditions of increased cardiac workload, via AMPK activation and ACC280 inactivation; LPL is not mobilized in quiescent cardiomyocytes or non-working Langendorff hearts.\",\n      \"method\": \"In vivo isoproterenol administration; isolated working vs Langendorff heart preparations; AMPK and ACC phosphorylation assays; heparin-releasable LPL activity measurement\",\n      \"journal\": \"American Journal of Physiology – Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean mechanistic link between AMPK activation and LPL mobilization, single lab\",\n      \"pmids\": [\"15687106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Palmitoyl lysophosphatidylcholine (PLPC) mobilizes LPL to the coronary luminal surface via PKC activation in endothelial cells; PLPC is metabolized via phospholipase D to lysophosphatidic acid (LPA), which then signals from endothelial cells to mobilize LPL from cardiomyocytes.\",\n      \"method\": \"Isolated Langendorff heart perfusion; PKC inhibitor (calphostin); exogenous PLD and PLPC co-incubation with cardiomyocytes; endothelial cell PKC activation assays; heparin-releasable LPL activity measurement\",\n      \"journal\": \"Journal of Molecular and Cellular Cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitor and biochemical reconstitution, single lab\",\n      \"pmids\": [\"15522270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"STAT3 drives aberrant LPL expression in CLL cells: STAT3 binds the LPL promoter (confirmed by ChIP), activates LPL promoter-driven luciferase reporter constructs, and STAT3 shRNA knockdown reduces LPL transcript and protein; LPL-mediated triglyceride hydrolysis provides free fatty acids that CLL cells oxidize for energy, and LPL siRNA knockdown reduces FFA oxidation and CLL cell viability.\",\n      \"method\": \"Luciferase reporter assays; chromatin immunoprecipitation; STAT3 shRNA knockdown; LPL siRNA knockdown; fatty acid oxidation assays; cell viability assays\",\n      \"journal\": \"Molecular Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, reporter, KD with functional readout)\",\n      \"pmids\": [\"25733697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZHX2 transcriptionally suppresses LPL expression in hepatocytes, reducing lipid uptake; ZHX2 overexpression inhibits HCC cell proliferation and lipid deposition, and LPL overexpression reverses ZHX2-mediated inhibition of HCC cell proliferation, xenograft tumor growth, and lipid deposition.\",\n      \"method\": \"ZHX2 overexpression and knockdown in HCC cells and mice; LPL overexpression rescue experiments; xenograft tumor models; IHC correlation\",\n      \"journal\": \"Cell Death and Differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue experiment validates pathway position, single lab\",\n      \"pmids\": [\"31740790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LPL in cardiomyocytes promotes glycerol metabolism under ischemia via the LPL/AQP7/GPD2 axis: cardiomyocyte-specific LPL deficiency enhances cardiac dysfunction and apoptosis after myocardial infarction; glycerol released by LPL-mediated triglyceride hydrolysis is transported by AQP7 and metabolized by GPD2 to support ATP synthesis under ischemic conditions.\",\n      \"method\": \"Cardiomyocyte-specific LPL knockout mice; MI model; AQP7 and GPD2 deficiency models; GPD2 enzymatic activation assays; PPARα agonist rescue experiments\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean tissue-specific KO with defined ischemia phenotype, pathway position by multi-gene deletion\",\n      \"pmids\": [\"34807469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LPL activity regulates hepatic VLDL remnant clearance independently of the classical apoE-recognizing receptors (LDLr, LRP, VLDLr); this clearance involves heparan sulfate proteoglycans and scavenger receptor SR-BI; the bridging function of LPL/HL is not required for hepatic remnant association.\",\n      \"method\": \"AdLPL and AdAPOC1 adenoviral manipulation in lrp−/−ldlr−/−vldlr−/− mice; radiolabeled VLDL-like emulsion clearance studies; heparin competition; in vitro primary hepatocyte binding/internalization assays\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and adenoviral manipulation with radiolabeled lipoprotein tracking, single lab\",\n      \"pmids\": [\"18367731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LPL-mediated lipolysis of VLDL in endothelial cells induces upregulation of AU-rich mRNAs (IL-8, ESM-1, VCAM-1, GM-CSF, TNF-α) and activates the RNA-binding protein HuR (increased polysomal localization), suggesting that products of LPL lipolysis modulate endothelial gene expression via HuR-dependent mRNA stabilization.\",\n      \"method\": \"cDNA subtraction; porcine aortic endothelial cells incubated with LPL+VLDL; polysomal fractionation of HuR; AU-rich mRNA expression analysis\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, mechanistic follow-up limited to fractionation and expression\",\n      \"pmids\": [\"16494882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoE content on VLDL is a negative regulator of LPL-mediated triglyceride hydrolysis: APOE3 and especially APOE4 isoforms inhibit LPL lipolysis of VLDL in a dose-dependent manner in vitro, whereas APOE2 does not; VLDL apoC-II content did not correlate with hydrolysis rate across individuals.\",\n      \"method\": \"Novel in vitro LPL hydrolysis assay mimicking human plasma conditions; VLDL from 15 normolipidemic donors; MS protein quantification; exogenous APOE isoform addition experiments\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstituted assay with exogenous APOE addition and isoform comparison, single lab\",\n      \"pmids\": [\"34863862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LMF1 coexpression dramatically enhances LPL secretion and activity; introducing furin-resistant mutations (including one that adds an N-linked glycan to the furin recognition site) prevents LPL cleavage during secretion without altering enzymatic activity, stability, or in vivo function, providing a useful reagent for biochemical studies.\",\n      \"method\": \"HEK293 cell coexpression of LPL with LMF1; furin-resistant LPL mutants; LPL activity and stability assays; in vivo functional validation\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with activity/stability/in vivo validation, single lab\",\n      \"pmids\": [\"30318473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fasting reduces LPL activity in human subcutaneous adipose tissue by ~60% via induction of ANGPTL4 protein; LPL mRNA and protein levels remain unchanged. Insulin downregulates ANGPTL4 in primary human adipocytes, while cortisol and fatty acids upregulate ANGPTL4, establishing the hormonal mechanism linking nutritional state to ANGPTL4-mediated LPL inhibition.\",\n      \"method\": \"Human adipose tissue biopsies pre/post 26-hour fast; LPL activity assay; ANGPTL4 and LPL mRNA/protein measurement; primary human adipocyte culture with hormone treatments\",\n      \"journal\": \"Molecular Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clinical intervention with paired human biopsies plus mechanistic cell experiments, translates mouse findings to humans\",\n      \"pmids\": [\"32504883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ApoC-III primarily inhibits LDL receptor- and LRP1-mediated hepatic TRL clearance via apoE; in the absence of functional apoE (and SDC1), apoC-III ASO treatment still lowers plasma TG by increasing adipose tissue LPL activity, establishing that apoE determines whether apoC-III acts via hepatic clearance or LPL inhibition.\",\n      \"method\": \"ApoC-III antisense oligonucleotide treatment in Apoe−/−Ndst1f/fAlb-Cre+ mice; adipose tissue LPL activity assay; hepatic VLDL production and clearance studies; clinical volanesorsen data stratified by APOE genotype\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in double-KO mouse model plus clinical data, single lab\",\n      \"pmids\": [\"31092690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endothelial cells respond to hyperglycemia by increasing GPIHBP1 expression via a heparanase-PDGF-GPIHBP1 axis; increased GPIHBP1 enhances LPL shuttling across endothelial monolayers to the luminal surface, increasing cardiac fatty acid delivery in diabetes.\",\n      \"method\": \"Streptozotocin diabetic mice; in vitro endothelial cell glucose dose-response; heparanase activity modulation; GPIHBP1 gene/protein expression; LPL transcytosis assay across EC monolayers\",\n      \"journal\": \"American Journal of Physiology – Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro mechanistic link between hyperglycemia, heparanase, GPIHBP1, and LPL shuttling, single lab\",\n      \"pmids\": [\"24735886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANGPTL3/8 complex potently inhibits GPIHBP1-bound LPL activity (measured directly with recombinant proteins); ANGPTL3/8 plasma levels are positively associated with LDL-C and triglycerides in humans, consistent with its LPL-inhibitory function.\",\n      \"method\": \"Recombinant protein assays measuring ANGPTL protein/complex effects on GPIHBP1-LPL activity; dedicated immunoassays for ANGPTL3/8 in two large clinical cohorts\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstituted LPL activity assay with GPIHBP1-bound LPL, validated in large human cohorts\",\n      \"pmids\": [\"39392008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The LPL missense mutation L303F produces a functionally inactive enzyme: COS7 cells transfected with L303F mutant cDNA produce ~40% of normal LPL protein in cell lysates but secrete none into media, and LPL activity is completely absent in both lysates and media, indicating the mutation prevents secretion and abolishes catalytic activity.\",\n      \"method\": \"COS7 cell transfection with L303F mutant LPL cDNA; LPL mass and activity measurement in cell lysate and media; post-heparin plasma analysis\",\n      \"journal\": \"European Journal of Clinical Investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro expression with functional assay, single lab\",\n      \"pmids\": [\"12641539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Two novel LPL mutations cause type 1 hyperlipoproteinemia by distinct mechanisms: p.G256TfsX26 (frameshift) abolishes LPL secretion and activity; p.M404R allows minimal LPL secretion but abolishes enzymatic activity, as demonstrated in HEK293 cells and patient post-heparin plasma.\",\n      \"method\": \"HEK293 cell overexpression; LPL protein detection by Western blot in lysate and conditioned medium; LPL activity assay; pre- and post-heparin patient plasma analysis\",\n      \"journal\": \"Journal of Clinical Lipidology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional characterization with patient validation, single lab\",\n      \"pmids\": [\"27578112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LPL deficiency in macrophages (myeloid-specific KO) alters bone marrow-derived macrophage gene expression and reduces lipid uptake in the presence of VLDL in vitro, but does not alter lipid accumulation or inflammatory gene expression in tissue macrophages in vivo, nor does it affect plaque macrophage polarity during atherosclerosis regression.\",\n      \"method\": \"Global and myeloid-specific LPL KO mice; bone marrow-derived macrophage gene expression; lipid uptake assays; adipose tissue macrophage lipid quantification; flow cytometry (Ly6C monocytes); atherosclerosis regression model\",\n      \"journal\": \"Arteriosclerosis, Thrombosis, and Vascular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean tissue-specific KO with multiple in vivo and in vitro readouts, single lab\",\n      \"pmids\": [\"31434492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"V200A mutation in LPL alters both LPL secretion and enzymatic activity without affecting dimerization; N291S mutation selectively abolishes LPL enzymatic activity while leaving secretion and dimerization intact, as demonstrated by in vitro expression in HEK293T/17 cells and in patient post-heparin plasma.\",\n      \"method\": \"HEK293T/17 cell transient transfection; Western blot for LPL mass in lysate and media; LPL dimerization assay; LPL enzymatic activity assay; patient post-heparin plasma validation\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mutagenesis with patient validation, single lab\",\n      \"pmids\": [\"30685441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A robust expression system for recombinant human LPL was developed using Drosophila S2 cells co-transfected with LPL, LMF1, and soluble GPIHBP1; GPIHBP1 acts as a chaperone stabilizing LPL during synthesis and secretion; heparin-Sepharose affinity chromatography dissociates the LPL-GPIHBP1 complex for one-step purification of active LPL (4–28 mg/L).\",\n      \"method\": \"S2 cell expression system; co-transfection with LMF1 and GPIHBP1; heparin-Sepharose chromatography; LPL activity assays; thermal stability measurements (Tm); purification of multiple LPL variants\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with structural/stability validation, novel expression system demonstrated with multiple variants\",\n      \"pmids\": [\"34780727\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LPL is a secreted triglyceride hydrolase that requires LMF1 (and Sel1L) for ER maturation and secretion; after secretion it transiently binds HSPGs and is transported to capillary endothelial cells by GPIHBP1 (via GPIHBP1's Ly6 domain), where GPIHBP1-bound LPL mediates margination and lipolysis of triglyceride-rich lipoproteins; LPL activity is finely tuned by a network of inhibitors (ANGPTL3/8, ANGPTL4, ApoC-III, ApoE) and activators (ApoC-II, ApoA5 which blocks ANGPTL3/8), with postprandial restoration of full LPL activity in adipose tissue orchestrated by ANGPTL4/8-mediated plasmin generation; LPL also exerts non-catalytic functions including selective cholesterol ester uptake and lipoprotein particle internalization, and in specialized tissues (islets, cardiomyocytes) plays cell-type-specific roles in insulin secretion and ischemic energy metabolism.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"Human lipoprotein lipase (LPL) cDNA was cloned and sequenced, revealing a mature protein of 448 amino acids and identifying LPL as a member of a gene family that includes hepatic lipase and pancreatic lipase. Two distinct LPL mRNA species arising from alternative 3'-polyadenylation sites were detected in multiple tissues.\",\n      \"method\": \"cDNA cloning and sequencing\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational molecular characterization, primary sequence determination\",\n      \"pmids\": [\"3823907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"ApoC-III directly inhibits LPL activity in a non-competitive manner, as demonstrated by kinetic analyses of LPL-mediated hydrolysis of VLDL in the presence of purified ApoC-III-2, suggesting ApoC-III directly interacts with LPL.\",\n      \"method\": \"In vitro LPL activity assay with purified apolipoprotein, kinetic analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with kinetic analysis, replicated in subsequent work\",\n      \"pmids\": [\"3973011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"LPL catalyzes hydrolysis of the triacylglycerol component of chylomicrons and VLDL, providing non-esterified fatty acids and 2-monoacylglycerol to tissues, and also possesses non-catalytic functions including bridging lipoproteins to cell-surface receptors and proteoglycans. Domain-function relationships established multiple LPL functional regions.\",\n      \"method\": \"Review synthesizing biochemical, mutagenesis, and transgenic animal studies\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — synthesis of extensive experimental literature with domain-function mapping\",\n      \"pmids\": [\"12483461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Catalytically inactive LPL alone (in the absence of active LPL) is sufficient to mediate selective cholesterol ester uptake from triglyceride-rich lipoproteins, but triglyceride hydrolysis and whole-particle lipoprotein uptake require active LPL. This demonstrates distinct catalytic and non-catalytic receptor-bridging functions of LPL.\",\n      \"method\": \"Transgenic mouse models breeding catalytically inactive LPL transgene onto LPL-deficient backgrounds; radiolabeled lipoprotein uptake assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple transgenic mouse models with orthogonal readouts distinguishing catalytic from bridging functions\",\n      \"pmids\": [\"11751882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPIHBP1-bound LPL (not free LPL nor HSPG-bound LPL) is the principal determinant of triglyceride-rich lipoprotein (TRL) margination in heart capillaries. Fluorescence microscopy, infrared-dye-labeled lipoprotein assays, and EM tomography showed TRLs fail to marginate in Gpihbp1-/- mice even when LPL is expressed by endothelial cells and available on HSPGs.\",\n      \"method\": \"Fluorescence microscopy, quantitative lipoprotein margination assays, EM tomography in wild-type and Gpihbp1-/- mice\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal imaging and quantitative methods in genetic mouse model\",\n      \"pmids\": [\"24726386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sel1L, an ER-associated degradation adaptor protein, physically interacts with and stabilizes the LPL maturation complex comprising LPL and LMF1. In the absence of Sel1L, LPL is retained in the ER, forms protein aggregates, and is degraded primarily by autophagy rather than being secreted.\",\n      \"method\": \"Adipocyte-specific Sel1L knockout mice; co-immunoprecipitation; ER fractionation; autophagy inhibition experiments\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO with multiple orthogonal methods (co-IP, fractionation, rescue), replicated across cell types\",\n      \"pmids\": [\"25066055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"LPL is expressed in pancreatic islets and directly regulates insulin secretion: islet LPL suppresses insulin release. INS-1 cells with increased LPL activity secreted less insulin, and cells with antisense LPL knockdown secreted more insulin, establishing LPL as a novel regulator of insulin secretion.\",\n      \"method\": \"LPL-deficient mouse islet isolation; in vitro insulin secretion assays; AAV-mediated LPL overexpression and antisense LPL knockdown in INS-1 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with defined secretory phenotype readout, islets and cell line\",\n      \"pmids\": [\"10488074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HSPG-bound LPL in interstitial spaces is mobile and can detach from HSPGs to migrate to GPIHBP1 on capillary endothelial cells. This migration requires the Ly6 domain of GPIHBP1 (W109S mutation abolishes transfer) but not GPIHBP1's acidic domain. In vivo, GPIHBP1-coated agarose beads injected into GPIHBP1-deficient adipose tissue recruited LPL from adjacent adipocyte HSPGs.\",\n      \"method\": \"Cell culture mobility assays; GPIHBP1-coated agarose bead injection into adipose tissue of GPIHBP1-deficient mice; mutagenesis of GPIHBP1 domains\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo experiments with defined GPIHBP1 domain mutants\",\n      \"pmids\": [\"27811232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ApoC-III potently inhibits triglyceride hydrolysis by GPIHBP1-bound LPL to a greater extent than by free LPL. ApoC-III-enriched TRLs bound normally to GPIHBP1-bound LPL but were hydrolyzed more slowly. A natural ApoC-III variant (p.A23T) associated with low triglycerides showed reduced capacity to inhibit both free and GPIHBP1-bound LPL.\",\n      \"method\": \"Cell culture LPL-lipolysis assays with GPIHBP1-bound LPL on agarose beads; in vivo TRL binding assays in transgenic mouse hearts; recombinant apoC-III inhibition kinetics\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assays with GPIHBP1-bound LPL, supported by in vivo data and natural variant validation\",\n      \"pmids\": [\"28694296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ANGPTL4 binds LPL near the active-site lid domain and an adjacent alpha-helix, as mapped by hydrogen-deuterium exchange mass spectrometry and validated by chimeric LPL variants and LPL peptide mimetics. Binding of ANGPTL4 to the lid domain likely prevents substrate catalysis at the active site.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry; chimeric LPL variants; LPL peptide mimetics; in vitro LPL inhibition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — HDX-MS structural mapping validated by mutagenesis and functional assays\",\n      \"pmids\": [\"30591589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoA5 lowers triglycerides by suppressing ANGPTL3/8-mediated LPL inhibition rather than by directly activating LPL. ApoA5 associates with ANGPTL3/8 in human serum (demonstrated by immunoprecipitation-MS) and blocks ANGPTL3/8 from inhibiting LPL, but has no effect on ANGPTL3, ANGPTL4, or ANGPTL4/8-mediated LPL inhibition.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry; biolayer interferometry; functional LPL enzymatic assays; kinetic analyses\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical methods including MS, biophysical binding, and functional enzyme assays\",\n      \"pmids\": [\"33762177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LPL and ApoA5 bind the same leucine zipper-like epitope on the ANGPTL3/8 complex, consisting of N-terminal regions of ANGPTL3 and ANGPTL8 unmasked upon complex formation. An anti-ANGPTL3/8 antibody targeting this epitope potently blocked ANGPTL3/8-mediated LPL inhibition in vitro and dramatically lowered triglycerides in vivo.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry; molecular modeling; biolayer interferometry; in vitro LPL inhibition assays; in vivo mouse TG measurements\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural mapping by HDX-MS with functional validation in vitro and in vivo\",\n      \"pmids\": [\"35307397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The ANGPTL4/8 complex binds both tissue plasminogen activator (tPA) and plasminogen, enhancing tPA activation of plasminogen to generate plasmin (mimicking fibrin). Plasmin then cleaves ANGPTL4/8, releasing LPL from partial inhibition and restoring full LPL activity. This mechanism explains how postprandial adipose tissue achieves maximal LPL activity.\",\n      \"method\": \"Pulldown assays; in vitro plasmin generation assays; LPL activity assays with catalytically inactive plasminogen mutant (S760A) and PAI-1 controls\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted biochemical system with rigorous mutagenesis controls and multiple orthogonal methods\",\n      \"pmids\": [\"36763533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANGPTL4/8-mediated plasmin generation in adipose tissue selectively blocks inhibition of LPL by ANGPTL3/8 (via cleavage of ANGPTL3 within the ANGPTL3/8 complex), and also reduces inhibition by ANGPTL4, ANGPTL3, and ApoC3, while leaving ApoC2-mediated LPL stimulation unaffected. ANGPTL3/8 potently inhibits GPIHBP1-bound LPL activity.\",\n      \"method\": \"Recombinant protein LPL inhibition assays; functional assays with tPA + plasminogen system; GPIHBP1-LPL enzymatic activity assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted biochemical system with specific controls for each inhibitor, mechanistically coherent\",\n      \"pmids\": [\"37666362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The LPL S447X gain-of-function truncation (removing 2 C-terminal amino acids) does not increase specific enzymatic activity on synthetic or natural substrates, nor does it alter ANGPTL4 inhibition kinetics. However, LPLS447X enhances lipoprotein particle uptake to a greater degree than wild-type LPL, likely by exposing C-terminal residues implicated in binding lipoprotein uptake receptors.\",\n      \"method\": \"Purified recombinant LPLS447X and LPL dimer comparison; in vitro enzymatic assays; fluorescent lipoprotein uptake assays; LPL structural modeling\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive purified protein biochemistry with multiple assay modalities\",\n      \"pmids\": [\"27984852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Adiponectin increases LPL translocation to the cardiomyocyte cell surface via RhoA/ROCK-mediated actin cytoskeleton remodeling. Adiponectin stimulates RhoA activity, increases stress fiber formation, inhibits cofilin (reducing actin treadmilling), and this cytoskeletal remodeling is required for LPL translocation and subsequent heparin-releasable LPL activity.\",\n      \"method\": \"Primary adult rat cardiomyocytes; G-LISA RhoA activation assay; rhodamine-phalloidin immunofluorescence; immunofluorescence detection of surface LPL; heparin-releasable LPL activity assay; RhoA/ROCK inhibitor experiments\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in primary cells, single laboratory\",\n      \"pmids\": [\"21147877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Beta-agonist isoproterenol increases cardiac LPL activity at the coronary lumen only during conditions of increased cardiac workload, and this effect is associated with AMPK activation and ACC280 inactivation. Simply switching from Langendorff to working heart conditions (increased afterload) induces AMPK/ACC280 phosphorylation and enhanced heparin-releasable LPL activity.\",\n      \"method\": \"In vivo isoproterenol treatment; Langendorff and isolated working heart preparations; AMPK and ACC280 phosphorylation assays; heparin-releasable LPL activity measurements\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo experiments linking AMPK signaling to LPL mobilization, single laboratory\",\n      \"pmids\": [\"15687106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Palmitoyl lysophosphatidylcholine (PLPC) maintains high coronary luminal LPL activity via PKC-epsilon activation in endothelial cells. PLPC is metabolized via phospholipase D to lysophosphatidic acid (LPA), which then mobilizes LPL from cardiomyocytes. PKC activation is essential for this LPL recruitment.\",\n      \"method\": \"Isolated heart perfusion; PKC inhibitor (calphostin) experiments; endothelial cell PKC activation assays; exogenous PLD experiments with myocytes; LPL activity measurements\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection in intact organ and cell systems, single laboratory\",\n      \"pmids\": [\"15522270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endothelial cells respond to hyperglycemia by increasing GPIHBP1 expression, which enhances LPL shuttling across endothelial monolayers. Heparanase promotes GPIHBP1 expression by releasing PDGF from heparan sulfate proteoglycans, revealing a heparanase-PDGF-GPIHBP1 axis that regulates LPL-mediated fatty acid delivery to cardiomyocytes in the diabetic heart.\",\n      \"method\": \"Streptozotocin diabetic mouse model; in vitro endothelial cell glucose exposure; GPIHBP1 gene/protein expression; LPL transcytosis assay across endothelial monolayers; heparanase inhibition experiments\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro experiments with mechanistic dissection, single laboratory\",\n      \"pmids\": [\"24735886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Monoclonal antibodies against the Ly6 domain of GPIHBP1 (RE3, RG3) abolish LPL binding, while an antibody against the acidic domain (RF4) does not, demonstrating that GPIHBP1's Ly6 domain is specifically required for LPL binding. A Ly6 domain missense mutation (W109S) reduces antibody affinity and abolishes LPL binding.\",\n      \"method\": \"Monoclonal antibody generation; LPL binding assays with domain-specific antibodies; W109S GPIHBP1 mutant binding analysis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional antibody domain mapping with mutagenesis validation\",\n      \"pmids\": [\"27875259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A conserved cysteine mutation in GPIHBP1 (p.C63Y) abolishes LPL binding and causes severe chylomicronemia in vivo. The mutant GPIHBP1 reaches the endothelial cell surface but at ~70% lower levels than wild-type, and the protein is predominantly monomeric, demonstrating that cysteine-mediated structure of GPIHBP1's Ly6 domain is essential for LPL capture.\",\n      \"method\": \"Knock-in mouse model (GPIHBP1 p.C63Y); immunohistochemistry; plasma TG measurements; Western blot analysis of GPIHBP1 oligomeric state\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knock-in mouse with structural and functional analysis\",\n      \"pmids\": [\"28476858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"STAT3, constitutively activated in CLL cells, drives aberrant LPL expression by binding to the LPL promoter. Chromatin immunoprecipitation confirmed STAT3 occupancy at the LPL promoter; luciferase reporter assays demonstrated STAT3 activates the LPL promoter; STAT3-shRNA knockdown reduced LPL transcripts and protein. LPL-mediated triglyceride hydrolysis provides free fatty acids that CLL cells oxidize for energy.\",\n      \"method\": \"Luciferase reporter assays; chromatin immunoprecipitation; STAT3-shRNA knockdown; LPL-siRNA knockdown; fatty acid oxidation assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, reporter, KD) establishing STAT3→LPL transcriptional axis\",\n      \"pmids\": [\"25733697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LPL yield can be dramatically enhanced by co-expressing its maturation factor LMF1, and by introducing furin-resistance mutations (including an N-linked glycan addition at the furin cleavage site), without adversely altering LPL enzymatic activity, stability, or in vivo function.\",\n      \"method\": \"Recombinant protein expression in HEK cells; LPL enzymatic activity assays; stability measurements; in vivo lipid measurements\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — biochemical characterization of modified LPL with activity and stability validation\",\n      \"pmids\": [\"30318473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LPL expression in cardiomyocytes increases during myocardial infarction. Cardiomyocyte-specific LPL deficiency enhanced cardiac dysfunction and apoptosis after MI. LPL-derived glycerol is taken up via aquaporin 7 (AQP7) and converted by GPD2 to support ATP synthesis during ischemia, revealing an LPL/AQP7/GPD2 glycerol metabolic axis that protects the ischemic heart.\",\n      \"method\": \"Cardiomyocyte-specific LPL knockout mice; AQP7 and GPD2 knockout mice; MI model; cardiac function measurements; metabolic flux analyses\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic KO models with defined metabolic and functional readouts\",\n      \"pmids\": [\"34807469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Apolipoprotein E (ApoE) content on VLDL inversely correlates with LPL-mediated TG hydrolysis rate. Exogenous APOE inhibits LPL lipolysis in a dose-dependent manner; APOE3 and especially APOE4 isoforms are effective LPL inhibitors, whereas APOE2 is not. This implicates VLDL-associated APOE as a physiological modulator of LPL activity.\",\n      \"method\": \"Novel in vitro LPL hydrolysis assay mimicking human plasma conditions; VLDL from 15 normolipidemic donors; mass spectrometry lipoprotein proteomics; exogenous APOE addition experiments\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified components and isoform-specific analysis\",\n      \"pmids\": [\"34863862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fasting decreases LPL activity in human adipose tissue by ~60% without changing LPL mRNA or protein levels, concurrent with increased ANGPTL4 mRNA (+90%) and protein (+46%). Insulin downregulates ANGPTL4 in primary human adipocytes while cortisol and fatty acids upregulate it, establishing the mechanism by which fasting reduces adipose LPL activity via ANGPTL4 induction.\",\n      \"method\": \"Human adipose tissue biopsies (fasted vs. fed); LPL activity assays; ANGPTL4/LPL mRNA and protein measurements; primary human adipocyte cell culture with insulin and cortisol treatment\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — human tissue with mechanistic follow-up in primary cells, single study\",\n      \"pmids\": [\"32504883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ApoC-III inhibition (via antisense oligonucleotide) lowers plasma TG in mice lacking apoE and functional syndecan-1 by increasing LPL activity in white adipose tissue (not by improving hepatic TRL clearance), demonstrating that apoE determines the dominant mechanism of apoC-III action: with apoE, apoC-III primarily inhibits receptor-mediated TRL clearance; without apoE, apoC-III instead inhibits tissue LPL activity.\",\n      \"method\": \"ApoC-III ASO treatment in Apoe-/-Ndst1f/fAlb-Cre+ mice; LPL activity measurements in white adipose tissue; VLDL production and TRL clearance assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse model with specific metabolic readouts, single laboratory\",\n      \"pmids\": [\"31092690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LPL-mediated lipolysis of VLDL in endothelial cells induces upregulation of AU-rich mRNAs (IL-8, ESM-1, VCAM-1, GM-CSF, TNF-alpha) and activates HuR (an AU-rich mRNA stabilizing protein) by increasing its polysomal localization. The free fatty acids and lipoprotein remnants generated by LPL activity mediate these downstream gene expression changes.\",\n      \"method\": \"cDNA subtraction; porcine aortic endothelial cell culture with LPL + VLDL; HuR polysomal localization assay; qPCR gene expression\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single laboratory, single method for mechanism (cDNA subtraction/expression), limited functional follow-up\",\n      \"pmids\": [\"16494882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LPL regulation involves an extensive macromolecular interaction network: LPL oligomeric state (monomer/dimer) is central to its regulation, with dimeric LPL being the active form; multiple inhibitors (ANGPTL3/8, ANGPTL4, ApoC-III) and activators (ApoC-II, GPIHBP1) modulate activity through direct protein-protein interactions; and GPIHBP1 binding dramatically stabilizes LPL (Tm increases from ~35°C to ~58°C).\",\n      \"method\": \"Review synthesizing biophysical, structural, and biochemical studies including thermal stability measurements\",\n      \"journal\": \"Sub-cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — synthesis of biophysical measurements including experimentally determined Tm values\",\n      \"pmids\": [\"38963487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZHX2 inhibits lipid uptake in hepatocellular carcinoma cells through transcriptional repression of LPL. ZHX2 overexpression reduced LPL mRNA and protein; LPL overexpression reversed ZHX2-mediated inhibition of lipid accumulation and cell proliferation, establishing a ZHX2→LPL transcriptional regulatory axis in NAFLD-HCC progression.\",\n      \"method\": \"ZHX2 overexpression and KO in HCC cell lines; xenograft mouse models; luciferase reporter assays; ChIP; IHC in patient samples\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple experimental approaches (reporter, ChIP, rescue experiments) in cell lines and mouse models\",\n      \"pmids\": [\"31740790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An expression system co-transfecting Drosophila Schneider 2 cells with human LPL, LMF1, and soluble GPIHBP1 yielded 4–28 mg/L of pure active LPL. Heparin-Sepharose purification disrupted the LPL-GPIHBP1 complex. Active-site mutant S132A, lipid-binding mutant W390A-W393A-W394A, and furin-resistant R297A were all successfully purified, enabling biochemical characterization of LPL's functional residues.\",\n      \"method\": \"Recombinant protein expression in Drosophila S2 cells; heparin affinity chromatography; LPL activity assays; site-directed mutagenesis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — production and functional characterization of multiple site-directed LPL mutants\",\n      \"pmids\": [\"34780727\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LPL is a triglyceride hydrolase that acts at the capillary lumen, where it is transported from subendothelial interstitial spaces to GPIHBP1 on endothelial cells (GPIHBP1 binding dramatically stabilizes LPL and is essential for TRL margination); LPL activity is tuned by a complex regulatory network including activators (ApoC-II) and inhibitors (ANGPTL3/8, ANGPTL4, ApoC-III acting on the lid domain), by postprandial plasmin-mediated cleavage of ANGPTL4/8 that restores maximal LPL activity in adipose tissue, and by ApoA5 which suppresses ANGPTL3/8-mediated inhibition; beyond hydrolysis, LPL exerts non-catalytic functions including receptor-bridging for lipoprotein particle uptake, regulation of insulin secretion in islets, and promotion of selective cholesterol ester uptake, while its secretion depends on LMF1 and Sel1L-mediated ER quality control.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LPL is a secreted triglyceride lipase that hydrolyzes triglycerides in circulating lipoproteins at the capillary endothelium, serving as a central regulator of plasma triglyceride homeostasis and tissue fatty acid delivery. LPL maturation in the ER requires the chaperones LMF1 and Sel1L, which stabilize the folding intermediate and prevent aggregation and autophagic degradation [PMID:25066055, PMID:30318473]; after secretion, HSPG-bound LPL is captured by the Ly6 domain of endothelial GPIHBP1, which is essential for LPL transcytosis to the capillary lumen and for triglyceride-rich lipoprotein margination [PMID:24726386, PMID:27811232]. LPL catalytic activity is inhibited by ANGPTL4 (which blocks substrate access at the lid domain), ANGPTL3/8, and ApoC-III, while ApoA5 competitively blocks ANGPTL3/8-mediated inhibition at a shared leucine-zipper epitope, and postprandial restoration of adipose LPL activity is achieved by ANGPTL4/8-stimulated plasmin generation that cleaves and inactivates multiple LPL inhibitors [PMID:30591589, PMID:35307397, PMID:36763533, PMID:37666362, PMID:32504883]. Beyond lipolysis, catalytically inactive LPL mediates selective cholesterol ester uptake, and in specialized tissues LPL regulates pancreatic islet insulin secretion and supports cardiomyocyte energy metabolism under ischemia via the LPL/AQP7/GPD2 glycerol utilization axis [PMID:11751882, PMID:10488074, PMID:34807469].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing that LPL has a tissue-specific non-lipolytic role: islet-expressed LPL suppresses insulin secretion, revealed by gain- and loss-of-function experiments, demonstrating LPL functions beyond plasma triglyceride clearance.\",\n      \"evidence\": \"LPL+/−, LPL−/− islets and INS-1 cells with AAV overexpression or antisense knockdown of LPL\",\n      \"pmids\": [\"10488074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking LPL activity to insulin granule exocytosis undefined\", \"Whether the effect requires catalytic activity or is receptor-mediated unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Dissecting catalytic vs. non-catalytic functions: catalytically inactive LPL mediates selective cholesterol ester uptake but cannot lower plasma triglycerides or promote whole-particle lipoprotein uptake, separating lipolytic and bridging functions.\",\n      \"evidence\": \"Transgenic catalytically inactive LPL (Mck-N-LPL) on LPL-deficient mouse backgrounds with radiolabeled lipoprotein tracking\",\n      \"pmids\": [\"11751882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor(s) mediating LPL-dependent selective CE uptake not identified\", \"Whether non-catalytic uptake is physiologically significant in tissues other than muscle unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identifying signaling pathways that mobilize LPL to the coronary lumen: palmitoyl lysophosphatidylcholine acts through endothelial PKC and PLD-generated LPA to relocate cardiomyocyte LPL to the vascular surface.\",\n      \"evidence\": \"Isolated Langendorff heart perfusion with PKC inhibitor and exogenous PLD/PLPC; heparin-releasable LPL activity\",\n      \"pmids\": [\"15522270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling steps between endothelial LPA generation and cardiomyocyte LPL mobilization not delineated\", \"Not confirmed with genetic approaches\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linking cardiac workload to LPL availability: β-adrenergic stimulation mobilizes LPL to coronary lumen only under increased cardiac workload, via AMPK activation, coupling energy demand to fatty acid supply.\",\n      \"evidence\": \"Working vs. Langendorff heart preparations with isoproterenol; AMPK/ACC phosphorylation and heparin-releasable LPL\",\n      \"pmids\": [\"15687106\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AMPK phosphorylation target linking to LPL translocation not identified\", \"Single-lab finding without genetic AMPK manipulation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolving receptor requirements for hepatic remnant clearance: LPL promotes VLDL remnant clearance independently of LDLr/LRP/VLDLr, implicating HSPGs and SR-BI, and showing LPL's bridging function is dispensable for hepatic remnant association.\",\n      \"evidence\": \"Adenoviral LPL manipulation in triple receptor-KO mice with radiolabeled VLDL-like emulsions\",\n      \"pmids\": [\"18367731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contributions of HSPG vs. SR-BI not quantified\", \"Mechanism by which LPL enhances HSPG-mediated uptake unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Establishing GPIHBP1-bound LPL as the physiological form mediating TRL margination: GPIHBP1-bound LPL, not HSPG-bound LPL, is required for TRL capture in heart capillaries, redefining the functional platform for intravascular lipolysis.\",\n      \"evidence\": \"Fluorescence microscopy, IR-dye-labeled lipoprotein assays, and EM tomography in Gpihbp1−/− vs. wild-type mice\",\n      \"pmids\": [\"24726386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same requirement holds in all capillary beds not tested\", \"Stoichiometry of GPIHBP1-LPL complexes on endothelium unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying Sel1L as a required ER cofactor for LPL maturation: Sel1L stabilizes the LPL–LMF1 complex in the ER, and its absence causes LPL aggregation and autophagic degradation rather than secretion, revealing a quality-control checkpoint for LPL folding.\",\n      \"evidence\": \"Adipocyte-specific Sel1L KO mice; reciprocal co-IP; protein fractionation; autophagy inhibition\",\n      \"pmids\": [\"25066055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Sel1L acts as a chaperone or ERAD adapter for LPL folding intermediates not distinguished\", \"Role of Sel1L in non-adipose LPL-expressing tissues not examined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapping the LPL-binding interface on GPIHBP1: the Ly6 domain (specifically W109) is required for LPL binding and transfer from HSPGs, while the acidic domain is dispensable, defining the molecular basis of GPIHBP1-mediated LPL capture.\",\n      \"evidence\": \"HSPG-to-GPIHBP1 transfer assays, Ly6 domain mutants (W109S), monoclonal antibody panel, in vivo bead injection in Gpihbp1−/− mice\",\n      \"pmids\": [\"27811232\", \"27875259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of the LPL–GPIHBP1 Ly6 interface not available at this time\", \"Contribution of the acidic domain to LPL stability on the endothelial surface unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that GPIHBP1 Ly6 domain integrity is essential in vivo: a conserved cysteine mutation (C63Y) abolishes LPL binding, causing LPL mislocalization and severe chylomicronemia, confirming the Ly6 domain requirement in a physiological setting.\",\n      \"evidence\": \"Knock-in C63Y mouse model with plasma TG, immunohistochemistry, and CHO surface expression\",\n      \"pmids\": [\"28476858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether C63Y disrupts Ly6 fold globally or specifically the LPL contact site not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealing that ApoC-III is a direct, potent inhibitor of LPL catalysis especially when LPL is GPIHBP1-bound, and identifying a natural loss-of-function ApoC-III variant (A23T) with reduced inhibitory capacity.\",\n      \"evidence\": \"In vitro hydrolysis assays with free vs. GPIHBP1-bead-bound LPL; recombinant and transgenic mouse-derived apoC-III; natural variant comparison\",\n      \"pmids\": [\"28694296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ApoC-III interaction with LPL–GPIHBP1 complex not determined\", \"Whether ApoC-III displaces lipid substrates or allosterically inhibits LPL unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Characterizing the gain-of-function LPL variant S447X: it does not differ in catalytic activity or ANGPTL4 sensitivity but enhances lipoprotein particle uptake, suggesting C-terminal truncation exposes receptor-binding residues.\",\n      \"evidence\": \"Purified LPL vs. LPLS447X comparison in activity, ANGPTL4 inhibition kinetics, and fluorescent lipoprotein uptake assays\",\n      \"pmids\": [\"27984852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating enhanced uptake not identified\", \"Structural model awaits crystallographic confirmation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapping the ANGPTL4 inhibitory mechanism to the LPL lid domain: ANGPTL4 binds the lid and a nearby α-helix, blocking substrate access to the active site, explaining the molecular basis of ANGPTL4-mediated LPL inactivation.\",\n      \"evidence\": \"HDX-MS structural mapping, chimeric LPL variants, LPL peptide mimetic competition\",\n      \"pmids\": [\"30591589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full co-crystal structure of ANGPTL4–LPL complex not obtained\", \"Whether ANGPTL4 also promotes LPL monomerization via this interface not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Establishing that LMF1 co-expression dramatically enhances LPL secretion and activity, and that furin cleavage during secretion can be prevented without functional consequence, enabling production of intact recombinant LPL.\",\n      \"evidence\": \"HEK293 co-expression with LMF1; furin-resistant mutants; activity, stability, and in vivo validation\",\n      \"pmids\": [\"30318473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise mechanism by which LMF1 promotes LPL folding remains unknown\", \"Whether furin cleavage has a regulatory role in vivo not excluded\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Delineating the ApoC-III–apoE axis: ApoC-III primarily inhibits apoE-mediated hepatic TRL clearance, but in the absence of apoE, lowering ApoC-III increases adipose LPL activity, showing that apoE context determines which branch of TG metabolism ApoC-III controls.\",\n      \"evidence\": \"ApoC-III ASO in Apoe−/−Ndst1f/fAlb-Cre+ mice; adipose LPL activity; hepatic clearance studies\",\n      \"pmids\": [\"31092690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of ApoC-III's direct effect on LPL activity in adipose tissue not defined\", \"Human validation limited to clinical stratification\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying how ApoA5 modulates the ANGPTL regulatory network: ApoA5 physically associates with ANGPTL3/8 in human serum and selectively suppresses ANGPTL3/8-mediated LPL inhibition without directly affecting LPL, ANGPTL4, or ANGPTL3 alone.\",\n      \"evidence\": \"IP-MS, biolayer interferometry, and functional LPL enzymatic assays\",\n      \"pmids\": [\"33762177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific context of ApoA5–ANGPTL3/8 interaction not established in vivo\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Translating ANGPTL4-mediated LPL regulation to humans: fasting reduces human adipose LPL activity ~60% via ANGPTL4 protein induction (not LPL mRNA/protein change); insulin suppresses and cortisol/fatty acids induce ANGPTL4, establishing the hormonal logic of postprandial LPL regulation.\",\n      \"evidence\": \"Paired human adipose biopsies pre/post 26-hour fast; primary human adipocyte hormone treatments\",\n      \"pmids\": [\"32504883\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ANGPTL4/8 complex levels change in parallel in human adipose not measured\", \"Kinetics of LPL activity recovery upon refeeding in humans not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defining a cardiomyocyte-specific metabolic axis: LPL-derived glycerol is channeled through AQP7 and GPD2 to sustain ATP synthesis during ischemia, establishing LPL as an upstream regulator of glycerol-based energy metabolism in the stressed heart.\",\n      \"evidence\": \"Cardiomyocyte-specific LPL KO and AQP7/GPD2 deficiency models in MI; GPD2 activation assays\",\n      \"pmids\": [\"34807469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of glycerol vs. fatty acid oxidation to ischemic ATP not measured\", \"Pathway not validated in human cardiomyocytes\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that GPIHBP1 functions as a chaperone during LPL biosynthesis: co-expression with soluble GPIHBP1 and LMF1 in Drosophila S2 cells stabilizes LPL, enabling high-yield purification of active enzyme.\",\n      \"evidence\": \"S2 cell co-transfection system; heparin-Sepharose purification; thermal stability and activity measurements\",\n      \"pmids\": [\"34780727\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether GPIHBP1 chaperoning occurs in mammalian ER or only after secretion not resolved\", \"Structural basis of GPIHBP1's stabilizing effect on LPL not determined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapping the competitive epitope on ANGPTL3/8: LPL and ApoA5 bind the same leucine-zipper-like region formed upon ANGPTL3/8 complex assembly, providing the structural explanation for ApoA5's protective effect and enabling therapeutic antibody design.\",\n      \"evidence\": \"HDX-MS, biolayer interferometry, in vitro LPL assays, in vivo TG measurements with epitope-targeting antibody\",\n      \"pmids\": [\"35307397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of the ternary LPL–ANGPTL3/8 complex not solved\", \"Relative in vivo affinities of LPL vs. ApoA5 for the epitope not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovering a plasmin-based postprandial switch: ANGPTL4/8 recruits tPA and plasminogen to generate plasmin, which cleaves ANGPTL4/8 and ANGPTL3/8, abolishes ApoC-III inhibition, and restores full LPL activity while preserving ApoC-II activation—providing a unified mechanism for postprandial adipose LPL activation.\",\n      \"evidence\": \"Reconstituted biochemical assays with tPA, plasminogen, catalytic-dead S760A mutant, PAI-1, and multiple LPL inhibitor/activator combinations\",\n      \"pmids\": [\"36763533\", \"37666362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of plasmin generation at the adipose capillary surface not performed\", \"Whether plasmin also cleaves LPL itself under these conditions not tested\", \"Regulation of local tPA availability in adipose tissue not characterized\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Confirming that ANGPTL3/8 directly inhibits GPIHBP1-bound LPL (the physiological form) and showing clinical association of circulating ANGPTL3/8 with lipid traits in humans.\",\n      \"evidence\": \"Recombinant protein activity assays with GPIHBP1-bound LPL; dedicated ANGPTL3/8 immunoassays in two large human cohorts\",\n      \"pmids\": [\"39392008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ANGPTL3/8 inhibits LPL by the same lid-domain mechanism as ANGPTL4 not determined\", \"Tissue-specific clearance of ANGPTL3/8 not characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structural understanding of full-length LPL in complex with GPIHBP1 and its regulatory partners (ANGPTL3/8, ANGPTL4, ApoC-II, ApoC-III) is still needed to unify the multiple inhibitory and activating mechanisms into a single conformational framework.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structures of LPL with ANGPTL4, ANGPTL3/8, ApoC-III, or ApoC-II\", \"In vivo kinetics of plasmin-mediated ANGPTL cleavage at endothelial surface not measured\", \"Cell-type-specific transcriptional regulation of LPL (e.g., STAT3 in CLL, ZHX2 in hepatocytes) lacks integration into the systemic regulatory model\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 4, 9, 10, 22, 24]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [9, 10, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 23, 32]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 14, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3, 4, 9, 22, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 7, 8, 14]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [9, 19, 20]}\n    ],\n    \"complexes\": [\n      \"LPL-GPIHBP1\",\n      \"LPL-LMF1-Sel1L (ER maturation complex)\"\n    ],\n    \"partners\": [\n      \"GPIHBP1\",\n      \"LMF1\",\n      \"SEL1L\",\n      \"ANGPTL4\",\n      \"ANGPTL3\",\n      \"ANGPTL8\",\n      \"APOA5\",\n      \"APOC3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"LPL is a secreted triglyceride hydrolase that cleaves the triacylglycerol core of chylomicrons and VLDL at the capillary lumen, delivering free fatty acids and monoacylglycerol to tissues; it also exerts non-catalytic functions including receptor-bridging for lipoprotein particle uptake and selective cholesteryl ester uptake independent of its catalytic activity [PMID:12483461, PMID:11751882]. LPL is active as a homodimer, requires the ER chaperone LMF1 and the Sel1L-dependent ERAD pathway for proper folding and secretion, and is transported from subendothelial heparan sulfate proteoglycans to the endothelial surface by GPIHBP1, whose Ly6 domain is essential for LPL binding and which dramatically stabilizes LPL and is required for triglyceride-rich lipoprotein margination [PMID:24726386, PMID:25066055, PMID:27811232]. LPL activity is tuned by a network of protein regulators—activated by ApoC-II, inhibited by ANGPTL4 (which targets the active-site lid domain), ANGPTL3/8, and ApoC-III, with ApoA5 selectively blocking ANGPTL3/8-mediated inhibition—and postprandial restoration of adipose LPL activity is achieved through plasmin-mediated cleavage of inhibitory ANGPTL complexes [PMID:30591589, PMID:33762177, PMID:36763533, PMID:32504883]. Beyond lipolysis, LPL regulates insulin secretion in pancreatic islets and provides glycerol that supports cardiac ATP synthesis during ischemia via an AQP7/GPD2 metabolic axis [PMID:10488074, PMID:34807469].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Establishing that ApoC-III is a direct non-competitive inhibitor of LPL resolved how apolipoprotein composition of TRL particles modulates lipolysis rate.\",\n      \"evidence\": \"In vitro kinetic analysis of LPL-mediated VLDL hydrolysis with purified ApoC-III-2\",\n      \"pmids\": [\"3973011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Binding site of ApoC-III on LPL was not mapped\",\n        \"In vivo contribution of ApoC-III to LPL inhibition vs. receptor-mediated clearance was unresolved\"\n      ]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Cloning and sequencing of LPL cDNA placed the enzyme within a lipase gene family and provided the molecular tools for all subsequent structure-function studies.\",\n      \"evidence\": \"cDNA cloning and sequencing from human adipose tissue library\",\n      \"pmids\": [\"3823907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No three-dimensional structure was available\",\n        \"Catalytic residues and domain boundaries were inferred by homology, not experimentally defined\"\n      ]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that LPL expression in pancreatic islets negatively regulates insulin secretion revealed an unexpected extrahepatic, extra-adipose metabolic role for LPL.\",\n      \"evidence\": \"Gain- and loss-of-function experiments in INS-1 cells and LPL-deficient mouse islets with insulin secretion readouts\",\n      \"pmids\": [\"10488074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular mechanism linking LPL activity to suppression of insulin secretion was not defined\",\n        \"Relative contribution of lipolytic products vs. bridging function in islets was unknown\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that catalytically inactive LPL suffices for selective cholesteryl ester uptake separated LPL's non-catalytic bridging function from its hydrolytic activity, establishing dual functional modes.\",\n      \"evidence\": \"Transgenic mice expressing catalytically inactive LPL on LPL-null background with radiolabeled lipoprotein uptake assays\",\n      \"pmids\": [\"11751882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of receptors engaged by LPL bridging was not established\",\n        \"Structural basis for bridging vs. catalytic function was unknown\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of GPIHBP1 as the obligate endothelial platform for LPL-mediated TRL margination resolved how LPL reaches the capillary lumen and why HSPG-bound LPL alone is insufficient for intravascular lipolysis.\",\n      \"evidence\": \"Fluorescence microscopy, IR-labeled lipoprotein margination assays, and EM tomography in wild-type and Gpihbp1−/− mice\",\n      \"pmids\": [\"24726386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural details of LPL–GPIHBP1 interaction were not resolved\",\n        \"How GPIHBP1 stabilizes LPL at the molecular level was unknown\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that Sel1L physically interacts with LPL-LMF1 and is required for LPL ER exit defined the ER quality control pathway governing LPL biogenesis, explaining how misfolded LPL is triaged to autophagy.\",\n      \"evidence\": \"Adipocyte-specific Sel1L knockout mice, co-immunoprecipitation, ER fractionation, autophagy inhibition\",\n      \"pmids\": [\"25066055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Sel1L acts directly on LPL folding or on LMF1-LPL complex stability was unclear\",\n        \"Contribution of proteasomal vs. autophagic degradation under physiological conditions was not quantified\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapping GPIHBP1's Ly6 domain as the LPL-binding domain and showing that HSPG-bound LPL actively migrates to GPIHBP1 explained the directional transport of LPL from parenchymal cells to the capillary endothelium.\",\n      \"evidence\": \"GPIHBP1-coated agarose beads in Gpihbp1−/− adipose tissue; Ly6 domain W109S mutagenesis; monoclonal antibody domain mapping\",\n      \"pmids\": [\"27811232\", \"27875259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Kinetics of LPL transfer from HSPGs to GPIHBP1 in vivo were not quantified\",\n        \"Role of GPIHBP1 acidic domain in LPL stabilization vs. transport was not fully resolved\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Characterizing the LPL S447X gain-of-function variant showed it does not increase intrinsic enzymatic activity but instead enhances non-catalytic lipoprotein uptake, clarifying the mechanistic basis of a clinically important human variant.\",\n      \"evidence\": \"Purified recombinant LPLS447X vs. wild-type enzymatic, ANGPTL4 inhibition, and fluorescent lipoprotein uptake assays\",\n      \"pmids\": [\"27984852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Receptor(s) engaged by the exposed C-terminal region were not identified\",\n        \"In vivo significance of the enhanced uptake function was not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"HDX-MS mapping of ANGPTL4 binding to LPL's active-site lid domain provided the first structural explanation for how ANGPTL4 inhibits LPL catalysis by occluding substrate access.\",\n      \"evidence\": \"Hydrogen-deuterium exchange mass spectrometry, chimeric LPL variants, LPL peptide mimetics, in vitro inhibition assays\",\n      \"pmids\": [\"30591589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ANGPTL4 also destabilizes the LPL dimer through lid-domain binding was not resolved\",\n        \"ANGPTL3/8 binding site on LPL had not been comparably mapped\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that ApoA5 lowers triglycerides by specifically blocking ANGPTL3/8-mediated LPL inhibition—rather than directly activating LPL—placed ApoA5 within the ANGPTL regulatory network as a selective counter-inhibitor.\",\n      \"evidence\": \"Immunoprecipitation-mass spectrometry of human serum, biolayer interferometry, functional LPL enzymatic assays\",\n      \"pmids\": [\"33762177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of ApoA5–ANGPTL3/8 interaction was unknown at the time\",\n        \"In vivo tissue-specific contribution of ApoA5 to LPL derepression was not established\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapping the shared LPL/ApoA5 binding epitope on the ANGPTL3/8 leucine-zipper interface revealed how two endogenous regulators compete for the same inhibitory complex and provided a therapeutic antibody target.\",\n      \"evidence\": \"HDX-MS on ANGPTL3/8; biolayer interferometry; anti-ANGPTL3/8 antibody lowered TG in vivo\",\n      \"pmids\": [\"35307397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative affinity of LPL vs. ApoA5 for ANGPTL3/8 in physiological conditions was not quantified\",\n        \"Whether this epitope is accessible on GPIHBP1-bound LPL in vivo was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that ANGPTL4/8 acts as a plasminogen activation scaffold—generating plasmin that cleaves inhibitory ANGPTL complexes to restore LPL activity—provided a feedforward mechanism for postprandial adipose lipolysis.\",\n      \"evidence\": \"Reconstituted in vitro tPA-plasminogen-ANGPTL4/8 system with catalytically inactive plasminogen and PAI-1 controls; LPL activity assays\",\n      \"pmids\": [\"36763533\", \"37666362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo validation that plasmin generation at adipose capillaries is the dominant mechanism for postprandial LPL reactivation is lacking\",\n        \"Whether plasmin also cleaves GPIHBP1-bound ANGPTL complexes in situ was not determined\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The full structural basis of LPL dimer-to-monomer transition during ANGPTL-mediated inactivation, the identity of receptors that mediate LPL's non-catalytic bridging uptake, and the in vivo significance of LPL regulation by ApoE isoforms remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"High-resolution structure of ANGPTL4-bound or ANGPTL3/8-bound LPL has not been determined\",\n        \"Receptors mediating LPL bridging function are unidentified\",\n        \"In vivo role of ApoE isoform-specific LPL inhibition in human lipoprotein metabolism is not established\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2, 3, 9, 14]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 4, 7, 8]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 7, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3, 9, 12, 13, 25]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2, 4, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 11, 25]}\n    ],\n    \"complexes\": [\n      \"LPL homodimer\",\n      \"LPL-GPIHBP1 complex\",\n      \"LPL-LMF1-Sel1L maturation complex\"\n    ],\n    \"partners\": [\n      \"GPIHBP1\",\n      \"LMF1\",\n      \"SEL1L\",\n      \"APOC3\",\n      \"ANGPTL4\",\n      \"ANGPTL3\",\n      \"ANGPTL8\",\n      \"APOA5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}